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Complementary and alternative medicines (CAMs) have become the preferred 
medicine for many in replacement of conventional medicines due to cultural or 
financial reasons. Herbal CAMS, in particular, have become a popular choice of 
medicine for their purported health benefits. Green tea extract (GTE) contains the 
major catechins epigallocatechin-3-gallate, epicatechin gallate, epigallocatechin 
and epicatechin, all of which vary across different GTE products and have become 
the focus on research into its purported health benefits. However, there have been 
cases of GTE-induced hepatotoxicity, for which the biochemical pathways have 
not been characterised. This study elucidates compounds similarities and changes 
in catechin levels within several different GTE products, and biochemical 
pathways related to reactive oxygen species (ROS) production affected by acute 
GTE supplementation in an in vitro setting using metabolomic techniques. It was 
found that GTE hepatotoxicity significantly decreased amino acids, oxoacids and 
carboxylic acids at 1 mg/mL exposure but produced a different metabolite profile 
upon 0.1 mg/mL exposure. The results demonstrate that GTE hepatotoxicity is a 
dose-dependent process that induces ROS production, ATP depletion and 
apoptosis, which corroborates prior knowledge on this topic. These results utilise 
a novel field of research, metabolomics, to add insight into the biochemical 
mechanisms of GTE hepatotoxicity and to observe the mass spectral pattern and 
levels of four catechins in different GTE products: (+)-catechin, (-)-epicatechin, 
(-)-epigallocatechin and (-)-epigallocatechin-3-gallate. This will allow consumers 
to become more aware of herb-induced liver injury and provide data to aid the 
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1. Literature Review 
1.1 Introduction 
Medicines have been an important part of human health for many centuries and 
have revolutionised the way diseases are diagnosed, treated, and managed. One 
of the oldest known forms of medicine is homeopathy, created by Samuel 
Hahnemann in 1796.1 Homeopathy applies the notion of ‘natural healing’, where 
diluted substances are administered to mimic symptoms of the disease in belief it 
will treat it. This ultimately became one of the most popular forms of alternative 
medicine.1 Conventional medicines directly contradict Hahnemann’s ideology, 
with the aim to eliminate and eradicate diseases through vaccines and 
pharmaceutical drugs. Research on conventional medicines has improved quality 
of life and life expectancy.2 Furthermore, the pharmaceutical industry in Australia 
is booming as individuals spent approximately AU$10.8 billion on medicines in 
2015-16.3  The Pharmaceutical Benefits Scheme (PBS) in Australia has made it 
easier and more affordable to obtain medicines, where eligible people can obtain 
certain medicines free of charge. Despite easy access to conventional medicines in 
Australia, many individuals are still turning to complementary and alternative 
medicines. This brings into question the chemical composition in these medicines 
and the patient’s susceptibility to a toxic reaction. 
1.2 Complementary and alternative medicines 
Since the 1970s, holistic practices have become more prevalent instead of newly-
developed pharmaceutical drugs to treat and maintain human disease.4 These 




“unconventional” medicines, but are most commonly known as complementary 
and alternative medicines (CAMs). Complementary medicines are those that are 
used in conjunction with conventional medicines, whereas alternative medicines 
are those used to replace conventional medicines and which are not normally 
integrated into a country’s health care system.5 CAMs encompass a range of health 
practices and consumer products, including: traditional Chinese medicine, Indian 
Ayurveda medicine, vitamin and dietary supplements, homeopathy, acupuncture, 
yoga, and spiritual practices.  
In Australia alone, the CAM industry has had a growth of AU$2 billion since 2014, 
which is expected to further increase.6 The same report by Complementary 
Medicines Australia indicated that there are approximately 8.1 million consumers 
who regularly purchase CAMs.6 Interestingly, there is an increasing CAM usage 
trend in females aged 45 years old or above, of Caucasian descent, of those who 
are married, possess tertiary qualifications and have private health insurance.7-11 
Many individuals use CAMs for their acclaimed health benefits, such as: the use 
of dietary supplements for fat loss, antioxidant properties and brain function 
improvement. Disturbingly, a significant portion of patients with chronic illnesses, 
such as cancer,8,12 gastrointestinal diseases,13 and respiratory illnesses like 
asthma,14 turn to CAM for treatment or management of their disease in preference 
to professional medical advice. This may be due to cultural beliefs, distrust or 
dissatisfaction with current conventional medicines, and the feeling of ‘taking 
control’ of their treatment.8,12,15  
Although there is evidence that pharmacists and physicians are a primary source 




approximately 33% of consumers report CAM use to their practitioner.16 Common 
reasons for this include: fear of judgement from physician; lack of knowledge from 
physician; and, alarmingly, the physician not asking during initial assessment.16 
Physicians feel that they should be more educated on the most prominent CAMs17 
and should communicate this with their patients as the history of medication usage, 
including CAMs, is paramount in determining causality for disease. A portion of 
physicians and pharmacists, not involved in practicing naturopathy, believe that 
CAM should be incorporated into conventional practices. This is to provide the 
best outcome and satisfaction for the patient, despite expressing fears of 
inadequate safety regulations.15,18 Regardless, consumers still choose CAMs over 
conventional medicines for reasons other than wellness. Up to 54% of consumers 
in under-developed countries use CAMs as conventional medicines are too 
expensive.12 Despite their proposed health benefits, some of which are yet to be 
scientifically validated, the use of CAM remains controversial.  
1.2.1  Herbal CAMs 
Herbal CAMs (HCAMs), by definition, are complex active ingredients from plants 
or plant-derived products that are used for medicinal purposes5 and have been used 
in traditional medical practices for centuries. An example of a popular HCAM 
that has been used consistently in the past, and still used today, are the Chinese 
herbal medicines (CHMs). These CHMs consist of a complex mixture of herbs, 
not always from plant products, and are used as a ‘cure’ for any imbalance of 
energy forces.5  
HCAMs generated up to AU$690 million in sales in 2017.6 A 2009 report from 




approximately 43.7% of all CAM sales in the USA, making them one of the most 
commonly consumed CAM.19 The purchasing of HCAMs has become less 
challenging as they can be readily purchased through supermarkets, pharmacies, 
and the internet,6 which contributes towards such staggering sales figures. While 
research into HCAMs has increased over the last decade, the molecular 
complexity of many HCAMs remains unknown. This, combined with the ease in 
acquiring these products,6,13 has led to concerns by researchers about the efficacy, 
safety and appropriate regulation of these medicines. 
1.3 Regulation of CAMs 
The World Health Organisation (WHO) first introduced the “WHO Traditional 
Medicine Strategy” in 2002 with the intention of improving the safety, efficacy 
and quality of CAMs worldwide. The WHO recently updated their strategy and 
introduced the “WHO Traditional Medicine Strategy 2014-2023” to combat 
challenges experienced by many WHO members, such as: the enforcement of the 
policies outlined by the strategy; effective education about CAMs to physicians, 
and most importantly, the development of a standard assessment for the efficacy, 
safety and quality of CAMs.5 In their initiative, the WHO has acknowledged that 
there must be evidence in order to integrate CAMs into conventional health care.5 
As such, there is a push towards the development of ‘evidence-based practice’ 
(EBP) policies for CAMs; regulatory bodies across the world share a common goal 
of protecting the consumer and, justifiably, many believe that ensuring the safety 





The pressure to employ EBP in CAM research has been met with criticism from 
philosophers and those with traditional cultural beliefs. Despite a large abundance 
of randomised controlled trials on CAMs, there is weak evidence towards positive 
clinical effects of CAM, and some have claimed that there is bias towards 
publication of positive results.21 The source of information about CAMs that 
consumers gather can influence their decision on choosing certain treatments,13 
and bias in published research can provide consumers with undue optimism. 
Consumers may view these ambiguous positive results as a quicker and cheaper 
fix to their illness(es), which can be detrimental for their health and to a 
researcher’s reputation.  
In addition, the availability of broader choice in the health care system creates 
potential ethical dilemmas.22 Whether it be for financial, economic or cultural 
reasons, many have no alternative but to use CAMs in conjunction with or in place 
of conventional medicines. This seems to perpetuate an unequal health care 
system where, in general, those with higher incomes in Western societies have 
access to safer and more efficacious treatments. It has therefore been questioned 
whether the regulation of CAMs should be left up to governing public health 
bodies,22 as there is evidence that consumers seek to educate themselves about 
CAMs and their safety.8,13 However, the integration of CAMs into conventional 
health care systems requires rigorous changes to current legal and regulatory 
systems.23 Thus, those that are disadvantaged may be concerned about harsher 





1.3.1  Regulation in Australia 
 
The Australian Government passed the Therapeutic Goods Act 1989 to manage and 
secure the manufacture, exportation, importation, supply and testing of CAMs. 
All CAMs and other therapeutic goods are regulated by the Therapeutic Goods 
Administration (TGA), which is a division of the Department of Health. Currently, 
CAMs are divided into two separate categories using a risk management 
assessment of ingredients: “registered” medicines, which include prescription 
medicines and many over-the-counter medicines; and “listed” medicines (AUST 
R and AUST L labels, respectively).24 The key differences between registered and 
listed medicines are that: efficacy is not evaluated by the TGA for listed goods, 
and goods solely for exportation are exempt from being registered.24 If approved, 
medicines are added to the Australian Register of Therapeutic Goods (ARTG), a 
database showing all therapeutic goods that are registered, listed, and under 
review.  
In Australia, HCAMs and their specific ingredients, such as herbal extracts, can 
also be categorised either as listed or registered medicines on the ARTG. The TGA 
released a guidance document in 2011 outlining herbal extracts that are equivalent 
to ingredients currently approved by the TGA, and thus may be used as an 
alternative ingredient in the manufacture of therapeutic goods.25 Factors such as 
geographical location and solvent used in the extraction of herbs can influence the 
extraction profile and, therefore, variation in batches occur.25 This document 
outlines which parameters can influence the native extract ratio (the ratio of the 
mass of the herbal material to the resulting material extracted from the herbal 




Although Australia has one of the most rigorous regulatory systems in the world, 
the framework has been met with criticism. In particular, there have been 
numerous concerns raised to the Complaints Resolution Panel regarding the 
compliance of advertisements in relation to the Therapeutic Goods Advertising 
Code (TGAC), primarily with the pre-approval process for advertisements. The 
TGAC prevents misleading information being presented in advertisements and 
requires all medical benefits and risks be accurately portrayed.26 Failure to comply 
with the TGAC could result in the manufacturers receiving up to five years 
imprisonment or 4,000 penalty units (a fine of approximately AU$645,000), or 
both.26  
1.3.2 Efficacy and safety concerns 
 
Concerns persist regarding the efficacy and safety of CAMs, primarily due to 
limited research. Of those studies that have been published, many did not apply 
EBPs, resulting in controversy and conflict between CAM and conventional 
medicine users. Tanaka and colleagues27 theorised a mathematical model that 
demonstrates that the most efficacious treatments with strict requirements for use 
may not always become popular and widespread compared to other ineffective 
treatments, such as CAMs. They argue that ineffective treatments can prolong 
illness time and therefore elevate purchase of these inefficacious treatments. 
However, some medical researchers have argued that the efficacy of evidence-
based conventional medicines is also of concern. This has been proposed to be due 
to a growing concern about physicians being unaware of evidence-based medical 
guidelines,28 which can affect the administration of appropriate medication to 




seminars to improve on knowledge have been implemented that has improved this 
particular issue.29 
With the growth in CAM sales, there has been greater concern amongst health 
practitioners as to the safety of CAMs. There are a variety of reasons for this 
increase in concern, including: lack of regulation, as previously discussed; lack of 
incident reporting, and the belief of CAMs being ‘natural’ and ‘safe’.30 A major 
concern is the potential for CAMs to interact or interfere with conventional 
medicines. Several reviews have not found compelling evidence or cases of such 
interaction with clinical significance,31,32 which could be due to the fact that 
potentially hazardous interactions are rare.33 
1.3.2.1  Safety concerns for HCAMs 
As with all CAMs, safety concerns with HCAMs arise due to a number of reasons, 
including: 
• Inadequate research data, funding for research, and support for research; 
• Lack of education and/or training, including health practitioners; and 
• Lack of expertise on HCAMs within public health authorities, and other 
relevant bodies.5,34 
The combination of these issues across many countries heightens the concern of 
HCAM safety; the lack of research data reduces the effectiveness of laws 
integrated into a public health system and could lead to malpractice or 
adulteration of traditional herbal preparations. For example, there have been cases 
where several herbal remedies were identified to have potentially fatal toxic metal 




Additionally, researchers are beginning to focus their research in herb-drug 
interaction (HDI), defined as complex components of HCAMs that interact with 
other conventional drugs to up- or down-regulate their actions. The chemical 
complexity of HCAMs can make research into understanding and characterising 
HDIs difficult. Thus, few studies have shown promising results of HDI of clinical 
relevance,11,36 but clinical cases and randomised clinical trials still exist.37 One such 
HCAM, green tea extract (GTE), has been the centre of attention for 
approximately 35% cases of potential HDI in recent years.11 This highlights the 
significance of GTE as a desirable herbal extract for research to clarify its safety 
and toxic potential.  
1.4 Green tea extract 
Green tea, obtained from the Camellia sinensis plant, is one of the most popular 
beverages in the world.38 Besides its brewed form, green tea can be consumed in 
extract form, which has led to its use as a popular dietary supplement. GTE is a 
popular dietary supplement taken in the form of a pill, powder or liquid. It differs 
from its brewed form such that an extract is synthesised using a non-alcoholic 
solvent to remove or select for certain compounds from green tea, therefore 
making it more concentrated.25 Its popularity has meant that more research is 
being conducted to investigate its therapeutic efficacy, including: fat reduction,39 
anti-cancer effects,40,41 and improvement of cardiovascular health.42  
The purported benefits of GTE have been linked to the presence of flavonoids, a 
sub-category of polyphenols. Flavonoids are naturally occurring, biologically 
active, organic compounds found in many foods and plants. GTE contains a sub-




in GTE are: (-)-epicatechin (EC); (-)-epigallocatechin (EGC); (-)-epicatechin 
gallate (ECG), and (-)-epigallocatechin-3-gallate (EGCG) (Figure 1.1). 
Collectively, these compounds are known as the catechins.43 EGC is the hydroxyl 
derivative of EC, whereas ECG and EGCG are the gallic acid derivatives of these 
two compounds. 
 
1.4.1  Catechins 
Catechins are found in a number of food products, such as black tea, apples, red 
wine, dark chocolate and berries. The catechin dry weight in GTE can reach up 
Figure 1.1. Molecular structures for the major catechins. (a) EC; (b) EGC; (c) ECG, 
and (d) EGCG. The flavan-3-ol backbone structure is highlighted in black.46 Variations 
in molecular structure are shown using different colours. 
 
Figure 1.2.1. Molecular structures for the major catechins. (a) EC; (b) EGC; (c) ECG, 
and (d) EGCG. The flavan-3-ol backbone structure is highlighted in black.46 Variations 





to 42% and varies depending on the season and growing location.43 As catechins 
comprise the majority of the complex mixture in GTE, they have been the main 
focus of research into both health benefits and potential toxicity. The catechins 
play a major role as antioxidants; specifically, they are involved in the clearance 
of over-saturated free radicals, such as reactive oxygen (ROS) and nitrogen species 
(RNS). By oxidising these free radicals that would otherwise lead to oxidative 
stress, the catechins prevent cellular and genetic damage. The low electrochemical 
potential of flavonoids, including catechins, increases free radical scavenging 
ability, creating a stronger antioxidant response.44 The high catechin content 
increases the antioxidant power of GTE, strengthening the perception that GTE 
is a highly valuable when integrated into the diet. 
The chemical structure of catechins consists of a general flavan-3-ol backbone, 
with a molecular formula of C15H14O2.
45,46 Variations of this general structure occur 
to form EC, EGC, ECG and EGCG, with the addition of a gallic acid at the C3 
position for ECG and EGCG (Figure 1.1). The biosynthesis of EC and EGC 
begins with phenylalanine and involves many enzymes of different functions, such 
as reductases and hydroxylases, to form cyanidin. This precursor, in the presence 
of nicotinamide adenine dinucleotide phosphate (NADPH), undergoes an 
important redox reaction with anthocyanidin reductase to form EC, and can 
further undergo a transferase reaction to add another hydroxyl to form EGC. A 
gallate is added to EC and EGC using flavan-3-ol gallate synthase to form ECG 
and EGCG, respectively. Catechin content can vary depending on the species, 
growing location, developmental stage47 and availability of light,48 all of which 
may affect the quality of GTE products. This variability further contributes to the 




One study suggests that catechins with gallic acid moieties (ECG and EGCG) 
have a higher potential to cause hepatotoxicity than EC and EGC in primary rat 
hepatocytes.38 Interestingly, another study found that the non-gallated molecules 
were mostly present in conjugated forms, whereas the gallated molecules were 
mostly present in free form in plasma.49 Plasma levels were heightened when 
human volunteers were fasting, thus ultimately increasing the bioavailability of 
the green tea catechins. These studies suggest that increased bioavailability, the 
molecular structure and the moiety of green tea catechins may induce GTE-related 
hepatotoxicity. 
1.5 The liver and hepatotoxicity 
Along with biliary and Kupffer cells, hepatocytes form the primary structure of the 
liver. Hepatocytes are the major functional cells of the liver which carry out the 
important task of filtering the blood for macromolecules, amino acids, fatty acids, 
toxins and other foreign compounds from the digestive tract, as well as 
transporting the filtered blood to the rest of the body. The liver undertakes other 
essential bodily functions such as protein synthesis, metabolism, detoxification 
and biotransformation of molecules. 
1.5.1  Liver metabolism 
While most organs and tissues possess the ability to biotransform various 
xenobiotics, such as drugs and alcohol, the most central site is the liver. A 
xenobiotic typically undergoes Phase I and Phase II metabolism. Phase I 
metabolism modifies the pharmacological activity of the xenobiotics and its 




deamination, which is often catalysed by enzymes such as isoforms of cytochrome 
P450 (CYP450).
50 This is followed by Phase II, which is biotransformation into a 
more polar substance for excretion through the kidneys. Common conjugation 
reactions that occur include methylation, glucuronidation, sulfation and 
acetylation. This process does not require the use of CYP450 as a catalyst, but 
instead uses transferases. Xenobiotics may also undergo Phase III metabolism, 
which uses transporters in the liver to export the inactive xenobiotic and its 
metabolites out of the liver and to the kidney for excretion via urine.50 The 
products of xenobiotic metabolism can also build up and can be detrimental for 
liver health, which may be a contributing factor in GTE hepatotoxicity. 
1.5.2  GTE hepatotoxicity 
Although researchers have suggested a possible dosage level for GTE 
hepatotoxicity in vivo and in vitro,38,51,52 it is an idiosyncratic disease, meaning it can 
be unpredictable in terms of the dosage and an individual’s molecular response. 
The rarity of GTE hepatotoxicity cases has made it difficult to determine the 
median lethal dose threshold (LD50) in humans, suggesting that it could be due to 
genetic diversity within the population that causes degrees of susceptibility to liver 
injury. Metabolic capacity also varies among individuals.  
Some individuals may metabolise xenobiotics rapidly and not experience a 
therapeutic effect, while others may have a toxic effect even at low doses due to 
slow metabolism. These are respectively known as ‘slow’ and ‘fast acetylators’, 
with differing arylamine N-acetyltransferase (NAT) enzyme activities due to 
polymorphisms of the NAT1 and NAT2 genes.53 Polymorphisms of these genes 




addition to the NAT enzymes, polymorphisms in the CYP450 gene pool also 
contribute to an individual’s response to xenobiotics, where particular isoenzymes 
have been identified as most significant.54 GTE hepatotoxicity has been 
demonstrated in genetically diverse animal models, with some mice tolerating 
exposure to GTE and some experiencing severe hepatotoxicity.55 Recent research 
suggests that the catechins in GTE can also affect functioning of some Phase I 
CYP450 isoenzymes, such as significantly inducing CYP1A156 and CYP3A4 
activity57 in the liver. Other studies showed that exposure to GTE had little to no 
effect on the functioning of the CYP450 isoenzymes, although have suggested that 
it inhibits CYP3A4 activity.58,59 This conflicting information enforces the 
idiosyncratic nature of GTE hepatotoxicity and results in significant challenges 
determining doses required for a toxic effect. The range of CYP450 isoenzymes 
that GTE up- or down-regulates could also affect measurement or characterisation 
of the biochemical mechanism of GTE hepatotoxicity. 
Available literature suggests that the biochemical mechanism of GTE 
hepatotoxicity is not fully understood. Furthermore, it is also not clear in which 
form the components of GTE induce their cytotoxic action. Studies to date have 
used liver function tests, biochemical assays and clinical symptoms to observe the 
end-point effects of the toxin. In addition, the diversity of xenobiotic metabolism 
rates within the population makes it difficult to observe GTE toxicity. There have 
been cases in recent years of hepatotoxicity suspected to be triggered by GTE,60-63 
leading to a phenomenon known as herb-induced liver injury (HILI). Interest into 
researching GTE hepatotoxicity gained traction after cases of hepatotoxicity 
involving the weight loss supplement Exolise were published.64 Upon review, 




available research conducted thus far has suggested that the catechins are likely 
involved in hepatotoxicity. With evidence of cases of HDI11 and hepatotoxicity 
involving GTE, it is paramount to identify the most likely native catechin(s) 
involved in disease and elucidate the biochemical pathways that may contribute. 
1.5.2.1  Green tea catechins and hepatotoxicity 
The available literature have attributed the hepatotoxic effects of GTE to the 
catechins and their potential pro-oxidant effects, namely increasing ROS 
production, particularly with high doses of EGCG.38,65 Excess ROS can be 
detrimental to cellular health; it can cause damage to the cell membrane, resulting 
in increased permeability and allowing toxins into the cell. GTE can also induce 
double base lesions in cellular and isolated deoxyribonucleic acid (DNA), 
accelerated in the presence of metal ions,66 which can result in mutations. Most 
importantly, the catechins have been found to collapse mitochondrial membrane 
potential (MMP).38 The MMP is an intermediate process formed from the 
production of the proton gradient during adenosine triphosphate (ATP) synthesis 
within cells. A drop in the MMP can lead to stunted ATP synthesis and has also 
been suggested to induce programmed cell death (apoptosis).67 However, the 
biochemical reasoning behind induction of oxidative stress has not been 
characterised in the literature. More specifically, it is poorly understood whether 
it is due to the accumulation of native GTE components or its metabolites. 
EGCG and ECG are typically the most abundant catechins, followed by EGC and 
then EC.68 EC abundance is low, ranging from 2-4% of the total catechin content,68 
but this does not limit its potential as a health benefit. The most popular use of EC 




doses, EC can suppress myostatin to prevent inhibition of skeletal muscle 
growth,69 and it has already been adopted by bodybuilders and those affected by 
muscular illnesses. While side effects are not well understood, there is no evidence 
to suggest that EC alone plays a role in hepatotoxicity.38,52 This could be due to 
the low relative abundance of EC in GTE, which may affect the overall dosage 
required to have a significant hepatotoxic effect. EGC has a greater potential to 
cause oxidative damage and mitochondrial membrane instability in hepatocytes 
than EC,38 but not enough to sustain a lethal cytotoxic response,52 suggesting that 
the gallic acid moiety may be involved in hepatotoxicity.38 
ECG is similar to EGCG in that they both possess a gallic acid moiety and it is 
only second to EGCG in inducing a hepatotoxic response.38 However, ECG has 
not been as extensively researched as EGCG.68 EGCG is known for its purported 
health benefits, and, as such, has been widely researched for its anti-cancer41 and 
weight loss properties through its antioxidant function.70 Although sometimes 
beneficial, its higher abundance in GTE has made EGCG the target for research 
into both acute and chronic hepatotoxicity. Lambert and colleagues51 attributed 
EGCG to dose-dependent hepatotoxic responses in vivo, which has also been 
demonstrated at high doses in vitro.65 Lambert showed that continuous oral doses 
of EGCG above 750 mg/kg can potentially cause irreversible damage to murine 
hepatocytes in vivo.51 Galati et al. showed that glutathione (GSH), a potent 
antioxidant involved in clearing damaging oxidants, decreased in the presence of 
EGCG, which contributed to increased ROS production.38 However, it is difficult 
to assess the toxicity of complex mixtures in humans, such as those in GTE, 







Figure 1.2. Summary of hypothesised means of GTE hepatotoxicity. Key: green = elucidated; 






The available evidence identifies EGCG as the most probable catechin to cause 
the most severe hepatotoxic effects both in vitro and in vivo. This is possibly due to 
its high abundance and antioxidant activity, which could induce an acute overdose 
in humans with a single dose of GTE. These studies have used animal models and 
clinical biochemistry assays to characterise hepatotoxicity of GTE. However, no 
suggestions have been made as to the biochemical pathway(s) affected by GTE 
and its catechins within human models, and so the exact pathways involved 
remain inconclusive. The hypothesised avenues of GTE hepatotoxicity are 
summarised in Figure 1.2. As GTE consumption is popular, a summary of the 
biochemical pathway(s) it modulates is required to determine if it is clinically 
relevant for consumers. 
1.5.3  Cases studies into GTE hepatotoxicity 
As the popularity of GTE has increased,4 there have been more reported cases of 
HILI related to GTE. A selection of these cases and clinical characteristics are 
summarised here, chosen on the basis of different individual responses and 
incidences reported most recently. 
Surapaneni and colleagues60 reported a case of suspected acute hepatocellular 
injury in the USA in 2017. A 50-year-old Caucasian woman presented with 
symptoms of weakness, decreased appetite, night sweats, severe itching, and 
jaundice-like symptoms. Liver function tests showed that the patient was 
experiencing elevated levels of total and direct bilirubin, aspartate 




liver illnesses such as hepatitis and herpes were negative. A liver biopsy showed 
enlargement of the hepatocytes (ballooning degeneration), confirming that hepatic 
necrosis had occurred. The patient revealed that they had been taking supplements 
that contained GTE once a day for one month. The authors concluded that GTE 
may have been the cause of severe acute hepatotoxicity using a Roussel Uclaf 
Causality Assessment Method (RUCAM), a point-based assessment method to 
determine the most likely cause of liver toxicity based on numerous factors. 
A case reported in 201361 showed a 16-year-old American Hispanic male who 
presented with jaundice-like symptoms. AST, ALT, conjugated bilirubin and 
unconjugated bilirubin were all significantly above normal reference ranges. 
Hepatitis and other viral tests were reported to be negative. The patient disclosed 
that they had a history of obesity and were taking a concoction of dietary 
supplements, including GTE. The patient was taking two pills per day for 60 days 
prior to admission to hospital, equivalent to 400 mg EGCG per day. A liver biopsy 
showed ballooning degeneration and cellular necrosis, similar to the previous case. 
The patient was given ursodiol and vitamin K and liver function tests gradually 
reverted to normal. The authors concluded that the herbal supplement was the 
most likely cause of liver failure, however, this was not determined by the 
RUCAM method or similar. 
A more serious case of hepatotoxicity was reported by Whitsett and colleagues.63 
In 2013, a 52-year-old American woman of unknown ethnicity presented to 
hospital with jaundice-like symptoms, vomiting and mild abdominal distension. 
The patient admitted to using GTE for two days whilst fasting. Total bilirubin, 




negative. A CT scan showed fluid build-up in the abdomen and a nodular liver. 
After a course of corticosteroids, the patient returned to hospital with worsened 
symptoms of hand tremoring (asterixis) and slurred speech, indicating that liver 
injury had progressed. Two days later, the patient underwent a liver transplant. A 
biopsy of the diseased liver was taken, with central cellular necrosis showing that 
hepatotoxicity had occurred most likely due to GTE. Again, the RUCAM was not 
applied in this conclusion. 
Another serious case occurred in Perth, Western Australia in 2015.62 A 26-year-
old Indigenous Australian male presented with jaundice-like symptoms and 
fatigue. Ten weeks prior to admission the patient had used two different dietary 
supplements for one week and discontinued use after developing rigors. Clinical 
liver function tests were conducted, and ALT, AST and bilirubin levels were 
severely elevated. The patient’s condition worsened, and he developed asterixis, 
whilst albumin depleted below the reference interval. A liver biopsy was taken and 
showed cellular necrosis. The patient underwent a liver transplant two months 
after initial presentation to hospital. The diseased liver was taken for 
histopathological testing and showed disorganised organ architecture with 
necrosis. Although more than one dietary supplement was used, the authors 
concluded that the most probable cause of this severe hepatotoxicity was GTE. 
The Council for International Organizations of Medical Sciences (CIOMS) scale 








Table 1.1. Summary of four cases of GTE hepatotoxicity. The age, sex, symptoms, 
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A summary of the cases can be found in Table 1.1. The cases involved patients 
from different ethnic backgrounds, ages and genders, showing that the dangers of 
GTE-containing products are not limited to specific groups. Results of the liver 
function tests were similar in all GTE hepatotoxicity cases, although alkaline 
phosphatase (ALP) levels were either normal or slightly elevated compared to the 
rest. This feature may rule out biliary cirrhosis and cholestasis,72 however, it is 
unlikely to be unique to GTE hepatotoxicity. The most common physical 
symptoms were the jaundice-like symptoms, with two of these cases progressing 
to worsened physical symptoms like asterixis, resulting in liver transplantation. 
This arises as a complication of a patient’s severe hepatic disease, which results in 
stunting the liver’s normal metabolic function and, therefore, build-up of toxic 
native molecules and/or its metabolites within the spinal cord and brain.73  
The histological, symptomatic and clinical features of GTE hepatotoxicity have 
been summarised and correlate to cellular necrosis of the liver, which is non-
specific to GTE hepatotoxicity and can be found in other liver diseases. These 
effects could be exacerbated for those with already damaged livers, such as heavy 
drinkers and obese patients.74 There are features, such as normal ALP levels and 
asterixis, that are conspicuous and potentially useful to medical practitioners. A 
new approach is required to characterise the biochemical mechanism of GTE 
hepatotoxicity. A modern and developing field of research, metabolomics, could 
be the key to characterising this biochemical mechanism. 
1.6 Analytical techniques 
Although initially used for in vivo studies, metabolomics has become increasingly 




human cell lines.75 The switch to in vitro studies has largely been due to the 
publication of ‘The Principles of Humane Experimental Technique’ by Russell 
and Burch in 1959. The three main aims of this document were the: replacement 
of animals with other methods; reduction in the number of animals used, and; 
refinement of techniques used to minimise the impact on animals.76 
In vitro hepatotoxicity studies use a variety of different cell types, such as primary 
human hepatocytes, human hepatoma cell lines, and adult stem cells. The human 
hepatocellular carcinoma cell line, HepG2, is one of the most popular cell models 
in human hepatotoxicity studies;75,77 it is a commercially available product that has 
a low cost, low biological variability and high reproducibility.77,78 This is in 
contrast to primary human hepatocytes, where functionality and life span is 
diminished over time when used in vitro,77 and thus not suitable for chronic 
hepatotoxicity studies. 
1.6.1  Metabolomics 
Metabolites are molecules of low molecular weight formed during metabolism and 
are necessary for driving essential cellular processes. They encompass a range of 
different molecules, including lipids, peptides and nucleic acids. Metabolites are 
influenced by both genetic and environmental stimuli, which results in a specific 
phenotype at a point in time.79 However, the complex nature of metabolism has 
made it challenging the metabolome to investigate due to transcriptional and post-
translational mechanisms, and protein-protein interaction networks required for 
functioning.80 Furthermore, metabolites vary in physicochemical properties such 





Metabolomics, the study of the metabolites formed within a biological sample (the 
metabolome), attempts to address this problem and has detected an increasing 
number of metabolites over time.82 This novel field of research began to gain 
traction in the 2010s.77 Other ‘omics’ approaches include genomics, 
transcriptomics and proteomics (Figure 1.3). Metabolomics is highly useful and 
differs from other omics fields in that it: (i) represents the final downstream 
phenotype of an organism to improve the link between cellular pathways and their 
biological mechanism, (ii) allows observation of abnormal changes in 
biochemistry before damage occurs,83 and (iii) brings a holistic approach to 
biochemical pathway and disease toxicity analysis compared to single marker 
techniques, such as assays. Therefore, metabolomics is a useful area of research 
for evaluating biomarkers of toxicity and mapping the affected pathways. 
 
Figure 1.3. The ‘omics’ cascade in successive order. Proteomics and metabolomics 




Metabolomics can be classified into targeted and untargeted analyses. Targeted 
analysis enhances sensitivity and selectivity to identify and quantify known 
metabolites of a sample. Whereas untargeted analysis can identify a broad scope 
of metabolites where prior knowledge of the metabolome for the sample is not 
required.79 Untargeted analysis is an excellent tool for the discovery of thousands 
of metabolites, and is most commonly analysed using a chromatography 
technique. 
1.6.2  Gas chromatography 
Chromatography allows for the separation of individual metabolites in a sample 
mixture by exploiting the ability of different compounds to interact with a 
stationary phase.84 The most commonly used chromatography techniques in 
metabolomics and toxicology are liquid (LC) and gas chromatography (GC).  
GC is one of the most widely used separation techniques in a variety of disciplines, 
including metabolomics. Generally, GC is the method of choice for the separation 
of volatile substances, such as non-polar molecules. Before analysis  of non-
volatile molecules can occur, the sample must be derivatised, typically using N-
Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA), which improves 
thermostability and increase volatility.84,85 In this way, derivatisation improves 
resolution of metabolites within a sample.85 The sample is introduced to the 
chromatogram inlet with a heated sample port to vaporise it. It is then mixed with 
the mobile phase, which is usually an inert gas such as helium or nitrogen. The 
mobile phase carries the sample mixture directly through a coiled column with 
contains the stationary phase. The stationary phase is either an inert liquid (termed 




chromatography).84 Separated compounds are detected by a detector, which 
reveals peaks corresponding to certain compounds (the chromatogram)86 (Figure 
1.4).  
Separation of the sample mixture is based predominantly on the vapour pressure 
of the compounds. For example, a compound that has been readily vaporised has 
a higher vapour pressure, which increases its elution or retention time. The 
opposite occurs for a compound that has a lower vapour pressure and tends to 
interact more with the stationary phase (Figure 1.4). Separation is also dependent 
on other factors, such as polarity. Different compounds with similar vapour 
pressures can be detected based on the strength of intermolecular interactions 
between the compound and stationary phases, improving chromatographic 
resolution. Many factors are considered when optimising the column for 
separation, such as polarity of the sample and stationary phase, and thickness of 





Gas chromatography-mass spectrometry (GC-MS) has been a well-established 
and standardised method of choice for the discovery of a variety of metabolites.87 
It is regarded as the ‘gold standard’ in metabolomics as it has high 
chromatographic resolution, sensitivity and reproducibility.88 Furthermore, the 
metabolomic databases for GC are more extensive than those for LC.82 The 
coupling of GC to MS has been used in in vitro hepatotoxicity studies in 70% of 
the literature,77 reinforcing its use as a ‘gold standard’ method.  However, the extra 
step of chemical derivatisation of an analyte can introduce problems in metabolite 
Figure 1.4. Schematic of GC workflow. (a) The carrier gas enters the inlet (b) and 
the heated inlet vaporises the sample being injected. (c) The gas carrying the 
vaporised sample enters the column for separation based on vapour pressure, 
illustrated in (f). (d) The sample molecules are measured using a detector. (e) The 
chromatogram is displayed on the computer. Molecules with a low vapour 









identification, especially when comparing mass spectra in large databases.89 The 
abundance of identified and quantified metabolites in GC databases, along with 
the standardisation of the technique, allows for high throughput untargeted 
analysis of GTE hepatotoxicity to address gaps in the knowledge of biochemical 
pathways affected by GTE. 
1.6.3  Mass spectrometry 
Two platforms are used to identify and quantify metabolites: nuclear magnetic 
resonance (NMR) and mass spectrometry (MS). NMR has the advantage of non-
destructive analysis and simple sample preparation.90 However, due to the 
relatively low sensitivity of NMR,90 MS has become the preferred analytical 
technique due to its high sensitivity and resolution.88  
A mass spectrometer is an instrument that can ionise molecules from a sample 
mixture and identify compounds based on their mass-to-charge ratio (m/z). The 
mass spectrometer has three main components to detect metabolites: the 
ionisation source, which ionises all fragments that enter; the mass analyser, that 
separates ions based on their m/z; and the detector, where the fragments strike a 
conductive surface to amplify the signal. A computer is attached to the mass 
spectrometer to visualise mass spectra and collate data for all compounds 






1.6.3.1  Electron ionisation 
The ionisation source ionises individual compounds to allow them to be 
manipulated within the electromagnetic field of the mass analyser. In GC-MS, the 
capillary column attaches to the sample inlet port of the MS ionisation source. The 
most common ionisation source when MS is coupled with GC is electron 
ionisation (EI).  
EI uses an electron beam to directly bombard the vaporised sample molecules with 
electrons at 70 electron volts (eV).86 Known as a ‘hard ionisation’ technique, it 
Figure 1.5. Schematic of general MS workflow. (a) The sample molecules (red) 
and electrons (black) collide at a perpendicular angle to ionise the sample 
molecules (blue). (b) The mass analyser separates the ionised sample molecules 
according to their m/z. An example of a mass analyser is a single quadrupole, as 
shown above. (c) The detector detects the molecule and amplifies the signal by 









uses high energy to fragment the ions and forms a unique fragmentation pattern 
per compound/ion.86 A heated filament ejects electrons perpendicular to the flight 
path of the sample molecules within the ionisation chamber. This causes the 
sample molecules to form positive ions, which move toward a series of lenses using 
a positively charged repeller and into the mass analyser. Finally, a vacuum draws 
out any uncharged molecules.85,86 The fragmentation pattern formed in EI is 
unique to a molecule and, by comparing the pattern to available mass spectral 
databases, such as the National Institute of Standards and Technology (NIST), 
unknown compounds can be identified. EI is particularly useful in the 
identification of unknown compounds that have not been added to a spectral 
database as it conveys structural information as well as information about 
molecular weight. 
1.6.3.2 Single quadrupole mass analyser 
Popular mass analysers used in MS include single and triple quadrupole (QQQ) 
analysers. A single quadrupole analyser consists of a set of four cylindrical rods 
where adjacent rods have a direct current (DC) and radio frequency (RF) signals 
applied to them.86 The ions move through the quadrupole at a stable trajectory 
based on their m/z. At a particular DC/RF combination, only ions of matching 
m/z will travel across the quadrupole toward the detector whilst keeping the 
DC/RF ratio constant. All other ions are deflected into the rods until their 
matching DC/RF combination is applied. The full m/z range is scanned by 
oscillating the DC/RF signals, usually from low to high voltages.  
QQQ operates in the same fashion as single quadrupole, except that three sets of 




instead of both DC and RF. A collision gas is added in Q2 to allow for further 
fragmentation of ions, and their m/z is measured using the final quadrupole, Q3.85 
Although QQQ has greater selectively and sensitivity,84 it is more often applied in 
targeted analysis of compounds due to its potential in identifying unique 
fragmentation patterns.77 Quadrupoles, in general, have lower costs, can detect a 
dynamic range of m/z (100 to 4000), and tolerate higher pressures compared to 
other mass analysers.88  
1.6.4 Data processing and deconvolution 
The output from MS analysis is called the ‘mass spectrum’. A typical mass 
spectrum shows the relative abundance on the y axis and the m/z on the x axis in 
the form of spectral peaks. The substantial amount of data acquired in untargeted 
analysis in MS can often be difficult to interpret manually. To avoid this, the data 
first undergoes spectral pre-processing to reduce the amount of background noise 
and low frequency ions, which removes any irrelevant data not associated with 
metabolomic changes.91 Deconvolution of spectra helps resolve overlapping peaks 
of different features (compound fragments), but relies on the use of existing 
spectral databases.91 Finally, normalisation of peak areas occurs using an internal 
standard to correct for variability in peak areas, and to accurately quantify detected 
metabolites in a sample.91 
Metabolomics often uses unsupervised and supervised multivariate analyses to 
identify metabolites with the most significant changes within a large data set. The 
most common unsupervised analysis is principal component analysis (PCA), 
which transforms variables into linear uncorrelated combinations, called principal 




component 1 (PC1) has the most variance, whereas PC2 is orthogonal to, i.e. 
statistically independent of PC1.92 Different groups that cluster closer together are 
highly correlated and show less variance, whereas those that are separated are less 
correlated.92 Unsupervised analysis is often used as a pre-processing method before 
undergoing supervised analysis. 
The most common supervised analysis in metabolomics is partial least square-
discriminant analysis (PLS-DA). It is similar to PCA in that it compresses highly 
dimensional data, but includes more variables during analysis, therefore 
describing variance among different groups of samples and creating a more 
powerful statistical analysis.77,91 It is highly accurate when larger numbers of 
variables are included, especially in mass spectrometry.93 This can aid in 
identifying significant metabolic patterns that occur in in vitro hepatotoxicity 
research.77 
1.7 Concluding statements and aims 
CAMs have become increasingly popular, and  a growing industry in Australia.6 
Despite purported health benefits, their efficacy and safety remains controversial. 
The potential importance of these safety risks is heightened as the current literature 
has suggested that the majority of consumers fail to report CAM use to medical 
practitioners,16 which is a major concern among the scientific community.15,18 
GTE has been a particular focus for research into hepatotoxicity with numerous 
cases having surfaced in the last few years.60-63 Due to its high abundance, EGCG 
has been the focus of research into the hepatotoxic effect of GTE.38,51,65 Researchers 
have suggested that the possible biochemical pathway for hepatotoxicity is due to 




This review has identified gaps in the knowledge of GTE hepatotoxicity, most 
notably regarding its poorly understood biochemical mechanisms. As it represents 
the final phenotype of an organism, metabolomics will provide more information 
on the biochemical mechanism and ascertain whether certain metabolites are up- 
or down-regulated in response to GTE. Gold standard techniques, such as GC-
MS, will be the key to clarifying these pathways. Ultimately, the combination of 
these techniques will contribute to the ongoing debate of safety and efficacy of 
GTE and other HCAMs. The literature has attributed tea catechins to inducing 
oxidative stress through ROS production and glutathione (GSH) depletion, and 
therefore it is hypothesised that GTE hepatotoxicity will identify biochemical 
pathways related to ROS production, ATP depletion and GSH depletion. 
This pilot study has four main aims to address the growing concerns of GTE 
hepatotoxicity:  
1) Identify and characterise, in detail, the biochemical components of 13 GTE 
products using untargeted single quadrupole GC-MS metabolomic 
analysis.  
 
2) Characterise CH, EC, EGC and EGCG abundance in 13 different GTE 
products using untargeted GC-MS analysis and compare to a NIST 
standard. 
3) Expose HepG2 cells to a commercial GTE product and catechin standards 
for 24 h at two different concentrations, 0.1 and 1 mg/mL, and measure 





4) Yield the intracellular metabolites from HepG2 cells and establish 
biochemical differences from GTE exposure at 0.1 and 1 mg/mL using 
untargeted single quadrupole gas chromatography-mass spectrometry 








































2. Materials and Methods 
2.1 Chemicals 
The powdered GTE product was purchased from a local health supplement store 
in Perth, Western Australia. All chemicals and reagents were used in its highest 
purity available. (+)-catechin hydrate (CH), (-)-epicatechin (EC), (-)-epicatechin 
gallate (EGC), and (-)-epigallocatechin gallate (EGCG) were all purchased from 
Sigma-Aldrich (St Louis, MO, USA). Seven other GTE products and six GTE-
containing products, including a GTE NIST standard reference material (SRM), 
were all obtained from a previous study conducted at Murdoch University and 
had been purchased from local pharmacies, health food stores and online. 
For cell culture, Dulbecco’s Modified Eagle Medium (DMEM), foetal bovine 
serum (FBS), penicillin-streptomycin and L-glutamine were all purchased from 
Sigma-Aldrich (St Louis, MO, USA). For metabolomic analysis, methoxyamine 
hydrochloride, n-alkanes (C10, C12, C15, C19, C22, C28, C32 and C36),  D-
13C6-sorbitol, 
pyridine and MSTFA were also purchased from Sigma-Aldrich. LC-MS grade 
water and methanol were purchased from Thermo Fisher Scientific (Waltham, 
MA, USA).  
2.2 Catechin abundance analysis 
2.2.1 Sample preparation 
Seven GTE products and six GTE-containing products were analysed with a GTE 
NIST standard reference material used as a sample reference. Some products 




extracted with 5 mL methanol (2 mg/mL). Any undissolved compounds were left 
to settle to the bottom of the tube to remove any impurities before analysis. 
Samples were diluted to 100 µg/mL using MeOH-sorbitol mix. Triplicates of each 
sample were prepared in 1.5 mL microcentrifuge tubes. Samples were dried in a 
Vacufuge Concentrator Plus and frozen at -80°C until ready for analysis.  
The highest purity of CH, EC, EGC and EGCG were all purchased from Sigma-
Aldrich (St Louis, MO, USA). The catechins were diluted to 100 ng/µL in 100% 
methanol and dried in a Vacufuge Concentrator Plus (Eppendorf, Hamburg, 
Germany) and frozen at -80°C until ready for analysis. A simplified workflow is 
detailed in Figure 2.1. 
2.2.2 Metabolomic analysis 
2.2.2.1 Derivatisation 
GTE samples and catechin standards were thawed and 20 µL of 20 mg/mL 
methoxyamine hydrochloride-pyridine mix added. Tubes were placed in a 
Thermomixer Comfort (Hamburg, Germany) at 30°C and 1200 rpm for 1.5 h. 40 
µL of MSTFA added to the tubes, which were put into the Thermomixer for 
another 30 mins at 37°C and 300 rpm. Tubes were centrifuged at 16.1 x 104 rcf for 
1 min. The total volume was transferred to GC vials with glass inserts, and 5 µL 
of n-alkane mix (C10, C12, C15, C19, C22, C28, C32 and C36) added. Vials were left for 




2.2.2.2 Instrumental analysis 
Untargeted metabolomic analysis was conducted using a Shimadzu GC-2010 Plus 
gas chromatograph with a 10 µL Shimadzu AOC-20i Auto Injector syringe and 
AutoSampler coupled to a Shimadzu GCMS-QP2010 series single quadrupole 
mass spectrometer (Shimadzu, Kyoto, Japan). The GC inlet was set to splitless 
mode and the GC-MS interface was set to 300°C. An Agilent FactorFour VF5-
5ms fused silica capillary column was used with high-purity helium 5.0 (Coregas, 
Yennora, Australia) used as a carrier gas for the analyte with a flow rate of 1 
mL/min. The initial oven temperature was programmed at 70°C and increased at 
a rate of 1°C/min for 6 min, which changed to 5.63°C/min thereon to reach a 
final temperature of 330°C. This gave a total sample run time of approximately 61 
mins. The injector was programmed to allow 5 pre-injection and 5 post-injection 
methanol washes. Exposure samples and control samples were randomised, with 
QC samples loaded every fifth sample. 1 µL of each sample was injected with the 
Shimadzu Auto Injector. The vaporised analytes were ionised using electron 
ionisation (EI) at 70 eV, with the ion source temperature set to 250°C. The scan 
rate for the MS was set to 10 scans/s and the scan range set to m/z  50-1000.  
2.2.2.3 Data analysis 
Data obtained from the GC-MS was imported into and deconvoluted using 
AnalyzerPro® (v5.5.1) and normalised to the 13C6-sorbitol internal standard peak 
areas. An automated library with all identified peaks was created using the GTE 
NIST SRM, and the targeted component library added to the data matrix. The 
data matrix was exported into an Excel spreadsheet and manually checked for 




Unscrambler® X v10.3 to perform PCA analysis to show differences between the 
different GTE samples, excluding outliers. 
The base peak and retention time for each catechin was found in each GTE sample 
and the fold change of each catechin was calculated, using the GTE NIST 
standard as the baseline catechin level. Separately, metabolites present in < 75% 
of replicates were excluded and identified by comparing mass spectra and 
retention times with the in-house library and NIST database. 
SPSS (IBM SPSS Statistics 24) was used to conduct a one-way ANOVA with 
Games-Howell post-hoc testing at a confidence interval of 95%. P < 0.05 was 
considered statistically significant. All data was considered normally distributed 







































13 GTE products and catechin standards extracted with MeOH-sorbitol mix 
Centrifuged and supernatant extracted  




Identification of catechins 
Determination of catechin abundance 
Analysis of GTE metabolites 
Figure 2.1. Simplified workflow of metabolomic analysis of the 13 GTE products 
and catechin standards and determination of catechin abundance. Order of 





2.3 GTE cell exposure 
2.3.1 Cell culture 
A simplified workflow is detailed in Figure 2.3. The human hepatocellular HepG2 
cell line was purchased from Sigma-Aldrich (St Louis, MO, USA) sourced from 
the European Collection of Authenticated Cell Cultures (ECACC acc. no. 
85011430), and frozen at -80°C at passage number 31 (P31). Cells were slowly 
thawed and grown in 75 cm2 flasks, supplemented with DMEM with 10% v/v FBS, 
1% v/v 10,000 U/mL penicillin-streptomycin and 1% v/v 2 mM L-glutamine. 
Cells were grown in 10 mL of DMEM and incubated at 37°C and 5% carbon 
dioxide (CO2) in a Thermo Fisher Scientific Heraeus BB15 Function Line CO2 
incubator (Waltham, MA, USA) at all times. Medium was changed 
approximately three times per week and cells were passaged once they reached 75-
80% confluency. 
For passaging and cell counts, cells were trypsinised by removing and discarding 
10 mL DMEM from the 75 cm2 flask and washing with 5 mL pre-warmed sterile 
PBS. PBS was removed and 2 mL pre-warmed 0.25% trypsin- 
ethylenediaminetetraacetic acid (EDTA) was added and incubated for 2-5 mins at 
37°C to dislodge cells from the flask surface. 8mL DMEM was added to terminate 
trypsination and gently pipetted to break up cell clusters. Cells were passaged 1:3, 
1:5 or 1:10 throughout the growth phase for use in exposure experiments or cell 
counting. For cell counting of 6-well exposure plates, the same procedure was 
followed using 20% of the original volumes. All experiments were performed in a 




2.3.2 Cell counting 
Both manual and automatic cell counts were undertaken following exposure 
experiments. The total cell count (cells/mL) and cell viability (%) were calculated 
using the Trypan blue exclusion method. Following trypsinisation, a 1:1 v/v ratio 
of cell mixture and 0.4% Trypan blue stain solution were added to a separate 1.5 
mL microcentrifuge tube and gently mixed with a pipette.  
For manual counting, 10 µL of the 1:1 v/v ratio was added to each side of a Bright-
LineTM Haemocytometer (Hausser Scientific, PA, USA). Viable cells were 
unstained by the Trypan blue, whereas non-viable cells were blue in colour due to 
membrane instability. Four 4 x 4 corner squares were used for cell counting, 
excluding cells falling on the bottom and right border. The total number of cells 
and viable cells were calculated in each quadrant and the mean was taken. 
Dilution factors were taken into consideration when calculating the final number 
of viable cells in cells/mL and recorded. 
For automatic counting, 10 µL of the 1:1 v/v ratio was added to each side of a 
NanoEnTek EVETM cell counting slide and inserted into a NanoEnTek EVETM 
Automatic Cell Counter (NanoEnTek, Seoul, South Korea). Non-viable cells stain 
dark blue due to the disruption of the cell membrane, whereas the intact cell 
membrane of viable cells do not take up the dye and appear pale under the 
microscope. The total cell count, viable cell count, non-viable cell count and cell 
viability percentage were automatically calculated by the machine and recorded. 
Both manual and automatic cell counting was conducted in these experiments to 




2.3.3 Cell treatment 
HepG2 cells at passage 31 at a density of 1 x 106 cells/mL were seeded into 6 x 6-
well plates (2 x quality control (QC), 2 x control and 2 x treatment plates) and 
DMEM added to make up a final volume of 2 mL per well. Cells were incubated 
at 37°C and 5% CO2 and left for 48 h to equilibrate prior to experimentation.  
GTE was dissolved at 10 mg/mL in DMEM without any additives (DMEM-/-) 
and left in the fridge at 2-8°C overnight. The 6 x 6-well plates were taken out of 
the incubator after 48 h and medium discarded. In the 2 x QC plates, 2 mL of 
DMEM-/- was added to each well. 1.8 mL of DMEM and 0.2 mL of DMEM-/- 
were added to 2 x control plates. 1.8 mL of DMEM and 0.2 mL of GTE solution 
was added to 2 x treatment plates, making the final GTE concentration 1 mg/mL. 
All plates were incubated for 24 h at 37°C and 5% CO2. The same procedure was 
followed for a second round of exposures to make the final concentration in each 
well 0.1 mg/mL at passage 31. A concentration of 0.1 mg/mL was chosen to 
reflect the recommended consumer’s dose as stated on the packaging. 1 mg/mL 
was chosen to induce an acute response and to ease identification of metabolites. 
2.3.4 Cell viability assay 
Cell viability was determined using the thiazolyl blue tetrazolium bromide (MTT) 
assay. MTT, a yellow-coloured compound, is converted to a dark blue formazan 
product in the presence of NAD(P)H-dependant oxidoreductases within viable 
cells to measure cell proliferation (Figure 2.2). The intensity of the blue formazan 









HepG2 cells at passage 34 at a density of 1.2 x 104 cells/mL were seeded into 5 x  
 
96-well plates (1 x GTE treatment, 1 x CH treatment, 1 x EC treatment, 1 x EGC 
treatment, and 1 x EGCG treatment) and serum-free DMEM (SF-DMEM) added 
to a final volume of 100 µL. Cells were left to equilibrate at 37°C and 5% CO2 and 
left for 48 h prior to experimentation. Four different concentrations of the 
catechins (control, 25, 50 and 100 µM) and GTE (control, 0.1, 0.5 and 1 mg/mL) 
were dissolved in SF-DMEM. Medium was discarded after 48 h and the different 
concentrations of each treatment added to the wells (Table 2.1). A total of 48 wells 
per plate (12 wells per treatment) were used for exposures excluding outer wells to 




Figure 2.2. Metabolic reaction of MTT (yellow) to formazan (blue/purple). MTT 
is reduced to formazan in the presence of NAD(P)H and intracellular 




Table 2.1. Concentrations of each treatment sample (GTE, CH, EC, EGC and 
EGCG) and their associated column number for the 96-well plate. The 




GTE CH EC EGC EGCG 
3-4 Control Control Control Control Control 
5-6 0.1 25 25 25 25 
7-8 0.5 50 50 50 50 
9-10 1.0 100 100 100 100 
 
The CellTiter 96® Non-Radioactive Cell Proliferation Assay protocol (Promega, 
Madison, WI, USA) was used throughout the cell viability experiment. 15 µL of 
Dye Solution was added to each well after 24 h and plates further incubated at 
37°C and 5% CO2 for 4 h. 100 µL of Solubilisation Solution was then added to 
each well and left overnight in a humid environment to allow solubilisation of the 
formazan product. The absorbance was read at 570 nm wavelength using a Tecan 
Spark 10MTM multimode microplate reader (Männedorf, Switzerland) with a 
reference wavelength of 660 nm. 
2.4 Metabolomic analysis 
2.4.1 Cell harvesting 
100 µg/mL of methanol and D-13C6-sorbitol (MeOH-sorbitol) internal standard 
was prepared to be added to exposure samples. Prior to use, it was kept in a 
refrigerator at 2-8°C. The mix was pre-chilled in a -80°C freezer for 30 min prior 




metabolism. Medium was discarded and cells washed with 500 µL PBS that was 
discarded. 500 µL of pre-chilled MeOH-sorbitol mix was added to 5 of 6 wells on 
each plate and cells scraped off using a cell scraper. The cell scraper was washed 
between each well with 70% ethanol, followed by PBS. Cells were transferred to 
1.5 mL microcentrifuge tubes for extraction. The sixth well was left for cell 
counting, as described in section 2.3.2. 
During counting of the sixth well on each plate, the cells exposed to GTE were 
found to be difficult to lift off of the wells using the appropriate amount of 0.25% 
trypsin-EDTA and length of incubation. This affected the true viability and total 
cell count; therefore, the experiment was repeated with the amount of 0.25% 
trypsin-EDTA and length of incubation adjusted to 500 µL and 8 minutes, 
respectively, to prevent inaccurate and unreliable cell counts. 
2.4.2 Extraction of metabolites 
Harvested cells were placed in a Precellys 24TM Tissue Homogeniser at 6500 rpm 
for 2 x 20 sec cycles (Bertin Technologies, Montigny-le-Bretonneux, France). The 
cells were removed and placed in a centrifuge (Eppendorf, Hamburg, Germany) 
for 5 min at 16.1 x 104 rcf. Supernatant was removed in equal volumes 
(approximately 300 µL) and added to fresh 1.5 mL microcentrifuge tubes. Tubes 
with supernatant were placed in an Eppendorf Concentrator Plus for 
approximately 2 h and placed in a -80°C freezer once dried. Derivatisation and 




2.4.3 Data analysis 
Data obtained from the GC-MS was imported into and deconvoluted using 
AnalyzerPro® v5.5.1 (SpectralWorks, Runcorn, United Kingdom). Data was 
normalised to the peak area of the 13C6-sorbitol internal standard and cell counts. 
QC samples were loaded onto the program and an automated library was created 
using identified peaks found in the QC samples. The targeted component library 
was then added to the GTE exposure sample data matrix. The data matrix was 
exported into an Excel spreadsheet and metabolites present in < 75% of replicates 
were excluded.  
The data matrix was then exported into The Unscrambler® X v10.3 (CAMO 
Analytics, Oslo, Norway) to perform PCA and PLS-DA analysis for visual 
representation of differences between the control and exposure samples. The data 
matrix was log10 transformed and mean centered prior to PCA analysis using non-
iterative partial least squares algorithm, cross validation and no rotation. The 
resulting PCA plot was used to help discriminate differences between the two 
sample groups. A supervised PLS-DA analysis was also conducted to identify the 
most probable metabolites involved in discriminating between the treatment 
groups. The loadings data matrix was subsequently extracted, and the unknown 
metabolites were identified by comparing mass spectra and retention times with 
the in-house library of metabolite standards (Metabolomics Australia, Murdoch 
University node, Australia) and the National Institute of Standards and 
Technology (NIST) mass spectral database (v2.3). Metabolite identification was 
based on the four levels of metabolite identification currently described in the 




search in the NIST database is the percentage probability, the Match and Reverse 
Match (R. Match) factors. The percentage probability indicates a compound that 
has similar or dissimilar mass spectra to other compounds. A higher percentage 
indicates a compound with dissimilar mass spectra to other compounds, and vice 
versa.95 The Match factors have a score out of 999 to denote the most likely mass 
spectral match between the unknown compound and  the library spectrum. An 
unknown spectra is prone to yielding lower Match factors,95 and was factored into 
the chosen criteria.  
A metabolite was considered a match if the probability was ≥ 20% and the Match 
and R. Match factor ≥ 700. If two out of three criteria are met, the compound was 
putatively identified but there was less confidence in the correct metabolite 
identified. A metabolite was identified based on its closest compound class if only 
meeting one of these criteria and its compound class was noted, such as 
“unidentified amino acid”, along with its retention time (RT). Any metabolite not 
meeting this criteria was denoted at “unknown” and its RT noted. Table 2.2 
outlines the criteria followed for metabolite identification. 
Table 2.2. The four levels of metabolite classification and their chosen criteria for 




≥ 20% probability 
≥ 700 Match 
≥ 700 R. Match 
Compound putatively identified 2/3 criteria met 
Compound class putatively identified 1/3 criteria met 




SPSS (IBM SPSS Statistics 24) was used to conduct a Student’s t-test or one-way 
analysis of variance (ANOVA) with Bonferroni post-hoc testing, as appropriate, 
with a confidence interval of 95%. P < 0.05 was considered statistically significant. 


































Derivatisation GC-MS analysis Data analysis 
Cell viability Harvesting Photography and 
cell counting 
Cell treatment 
Doses of GTE, CH, EC, 
EGC and EGCG added 
Cell culture 
6-well and 96-well 
plates seeded from 
flask 
Doses of GTE added 
1 well from each plate trypsinised 
Mixed with 0.4% trypan blue  
Washed with cold PBS 
Scraped into microcentrifuge 
tubes 
Overnight method used 
Absorbance read at 570 nm 
Extracted with MeOH-sorbitol mix 
Cells lysed and centrifuged 




grown in 37°C, 
5% CO2 
Figure 2.3. Simplified workflow for GTE exposure experimentation, as described in sections 
2.2-2.4.5. Order of events: Cell culture, cell treatment, cell viability testing, harvesting, 





3.1 Composition of GTE 
3.1.1 Chemical analysis of catechin standards 
Standards of CH, EC, EGC and EGCG were analysed using GC-MS. ECG 
standard could not be obtained within the budget of the project, so was not 
included. The retention time (RT) and base peak of each catechin standard was 
determined (Table 3.1). Within a mass spectrum, the base peak is the tallest peak 
with the greatest relative intensity (abundance), as seen in Figure 3.1. The RT and 
base peak of CH and EC were almost identical, where the RT was 44.5 and 44.2 
min, respectively, and both were observed to have a base peak of m/z 368. Due to 
the structural similarity of EC and EGC (Figure 1.1), the RTs were very similar 
(44.2 min and 45.15 min, respectively), differing by 0.95 min. However, the base 
peak for EC and EGC were m/z 368 and m/z 456, respectively, differing by m/z 
88. EGCG had the longest RT of 55.20 mins with a base peak m/z 648 due to the 
structural dissimilarity between EGCG and the other catechin standards. 
Table 3.1. Retention time (mins) and base peak (m/z) results of GC-MS analysis 
for catechin standards CH, EC, EGC and EGCG. 
 
 
Catechin RT (mins) Base peak (m/z) 
EC 44.20 368 
CH 44.50 368 
EGC 45.15 456 


































Figure 3.1. GC-MS mass spectra output for (a) CH, (b) EC, (c) EGC and (d) EGCG. Each 
peak shows relative intensity (%) and associated m/z. Red arrows indicate the base peak in 




3.1.2 Chemical analysis of GTE samples 
Figure 3.2 shows the PCA scores plot comparing the GTE and GTE-containing 
products. PC-1 explained 16% of the variance and explained the most variance 
between each GTE product. PC-2 explained 12% of the variance in the data, 
separating the NIST SRM from the dense cluster of GTE 290, 295, 300, 304 and 
305 samples. The grouping of samples along PC-1 and PC-2 showed there was 
relatively little variation in metabolite data between GTE 290, 295, 300, 304 and 
305.   
Table 3.2 shows the RT and base peak for the 16 compounds that contributed most 
to the variance between each GTE product, and the top matches as identified via 
the NIST mass spectral database. Statistical significance is indicated if there was 
at least one statistically significant difference between GTE products. In total, 16 
metabolites contributed to the most variance between each GTE product. A 
mixture of carbohydrates, fatty acids, carboxylic acids and organic compounds 
were present in each product. Many of the top matches had similar base peaks, 
with five of the 16 metabolites having a base peak of m/z 57, three with a base 
peak m/z 147, and two with a base peak of m/z of 117. Many of the top matches 
appeared to be similar despite differing RTs. An example is 9H-Carbazole-1-
carboxylic acid, 4-(1H-indol-3-yl)-, methyl ester, which has the same base peak 
















Figure 3.2. Principal component scores of the GC-MS data comparing GTE products. 
Grouping of sample sets is represented by coloured ovals (GTE NIST SRM = pale green; 
GTE 69 = red; GTE 239 = yellow; GTE 245 = black; GTE 248 = purple; GTE 289 = 
pale orange; GTE 290 = brown; GTE 295 = pink; GTE 300 = dark green; GTE 304 = 
dark orange; GTE 305 = blue; GTE 321 = grey; purchased GTE product = dark blue). 




Table 3.2. Retention time (mins), base peak (m/z) and the top match identified 
from the NIST database for compounds contributing most to the variance as 
identified through PCA. Statistical significance was observed using a one-way 
ANOVA with Games-Howell post-hoc testing as indicated by * = p < 0.05. 
RT (mins) Base peak (m/z) Top match 
13.202 147 N-Benzhydrylidene-1-(2,4,6-
trimethylphenyl)ethylamine N-oxide* 
13.480 113 1-Piperidinecarboxaldehyde* 
15.013 228 Ethanol, 2-(methylamino)-, N-trifluoroacetyl, 
O-tert-butyldimethylsilyl) 
16.517 110 N-(tert-Butyldimethylsilyl)trifluoroacetamide* 
17.612 107 N-Methyl-N-phenyl-N'-(3-ethoxyphenyl)-urea 
18.228 184 N-(tert-Butyldimethylsilyl)-2,2,2-trifluoro-N-
methylacetamide 
19.792 82 3-Methyl-4-oxo-2-pentenoic acid 
30.478 147 Galactose oxime, 6TMS derivative 
30.592 147 Benzylmalonic acid, 2TMS derivative* 
32.737 117 Palmitic Acid, TMS derivative 
35.912 117 Stearic acid, TMS derivative 
43.108 57 Timolol methylboronate 
45.482 57 9H-Carbazole-1-carboxylic acid, 4-(1H-indol-
3-yl)-, methyl ester 
47.713 57 9H-Carbazole-1-carboxylic acid, 4-(1H-indol-
3-yl)-, methyl ester 
49.810 57 4-Ethyl-2-octanol 
51.790 57 9H-Carbazole-1-carboxylic acid, 4-(1H-indol-
3-yl)-, methyl ester 
 
3.1.3  Relative catechin levels 
Twelve GTE and GTE-containing products were analysed compare the catechin 
abundance to the GTE NIST SRM. GTE products were collected as part of a 




local health stores, pharmacies, and online. GTE 239, 245, 295, 305, 321, and the 
GTE product purchased for this study were all labelled as GTE products. GTE 69, 
248, 289, 290, 300 and 304 were labelled as products containing GTE within their 
ingredients. All twelve GTE products and the NIST standard underwent GC-MS 
metabolomic analysis to observe the relative abundance of each catechin in each 
product compared to the NIST standard. All statistical analysis was conducted 
using a one-way ANOVA with Games-Howell post-hoc testing to compare each 
product to the NIST standard. 
Table 3.3-3.5 shows the relative level of each detectable catechin in each tested 
GTE product. CH was the only catechin that was not detectable in the NIST 
standard and the GTE products, and therefore removed from further analysis. EC 
could not be detected in 7 of the 12 products tested (GTE 69, 245, 289, 295, 300, 
304 and 321), with 4 of them being GTE-containing products. Of the 5 products 
in which EC was detected, 4 showed a higher relative amount compared to the 
GTE NIST standard. Three products (GTE 239, 305 and the GTE product 
purchased for this study) showed a significant increase of EC of 3.047-fold, 10.311-
fold and 9.998-fold, respectively (p < 0.026), with GTE 305 having the largest 
increase (p < 0.001). GTE 290 had a 1.138-fold increase in relative EC level, 
although was not significant (p > 0.05). GTE 248 had a 0.442-fold decrease 
compared to the NIST standard, the only decrease observed, which was not 
statistically significant (p > 0.05). 
EGC could be detected in 4 of the 12 products (GTE 69, 289, 295 and 300), of 
which the majority were GTE-containing products. 7 of the 8 GTE products 
detected for EGC had a lower relative level, ranging from 0.083 to 0.849-fold 




0.083-fold (p < 0.008), and GTE 305 was the only product with a higher relative 
level with a 1.556-fold increase, although this was not statistically significant (p > 
0.05). 
Across the products, EGCG was more varied, with some products having a higher 
and others a lower relative level compared to the NIST SRM. Similar to EGC, 
EGCG would not be detected in 4 products (GTE 69, 289, 295 and 300) of which 
the majority were GTE-containing products. Significantly different EGCG levels 
were only seen in GTE 239 (p < 0.040) and GTE 305 (p < 0.001), of which GTE 
305 had the highest relative level of 4.602-fold. In terms of lower relative levels, 
the most notable was GTE 245 which experienced a 0.091-fold decrease, however 
no statistical significance was observed (p > 0.05). 
There were only 3 GTE products (GTE 69, 295 and 300) where no catechins were 
detected, of which two were GTE-containing product and the other a GTE 
product. 5 of the 12 products had all three catechins detected (GTE 239, 248, 290, 
305 and the GTE product purchased for this study). Of particular interest is GTE 
305, which had a higher relative level of all catechins compared to the NIST 
standard, which were statistically significant for two compounds (p < 0.001). GTE 
248 had the opposite effect, with a lower relative level of all catechins, of which 
one compound was statistically significant (p < 0.005). EC was less reliably 
detected compared to EGC and EGCG, where three products were detected for 







Table 3.3. Relative level of EC for each GTE sample (n= 3) from the GTE NIST 
SRM. Key: green arrow = fold change above NIST SRM; red arrow = fold change 
below NIST SRM; - = EC not detected. Statistical significance was observed using 
a one-way ANOVA with Games-Howell post-hoc testing as indicated by * = p < 













GTE product Relative level (fold difference) 
GTE 69 - 
GTE 239 3.047* 
GTE 245 - 
GTE 248 0.442 
GTE 289 - 
GTE 290 1.138 
GTE 295 - 
GTE 300 - 
GTE 304 - 
GTE 305 10.311*** 
GTE 321 - 




Table 3.4. Relative level of EGC for each GTE sample (n= 3) from the GTE NIST 
SRM. Key: green arrow = fold change above NIST SRM; red arrow = fold change 
below NIST SRM; - = EGC not detected. Statistical significance was observed 
using a one-way ANOVA with Games-Howell post-hoc testing as indicated by * 















GTE product Relative level (fold difference) 
GTE 69 - 
GTE 239 0.849 
GTE 245 0.083** 
GTE 248 0.171** 
GTE 289 - 
GTE 290 0.759 
GTE 295 - 
GTE 300 - 
GTE 304 0.101** 
GTE 305 1.556 
GTE 321 0.193* 




Table 3.5. Relative level of EGCG for each GTE sample (n= 3) from the GTE 
NIST SRM. Key: green arrow = fold change above NIST SRM; red arrow = fold 
change below NIST SRM; - = EGCG not detected. Statistical significance was 
observed using a one-way ANOVA with Games-Howell post-hoc testing as 














GTE product Relative level (fold difference) 
GTE 69 - 
GTE 239 2.246* 
GTE 245 0.091 
GTE 248 0.623 
GTE 289 - 
GTE 290 1.276 
GTE 295 - 
GTE 300 - 
GTE 304 0.133 
GTE 305 4.602** 
GTE 321 0.247 





3.2 Analysis of GTE exposure 
Prior to metabolomic analysis, the human hepatocellular HepG2 cell line was 
cultured and exposed to 0.1 and 1 mg/mL GTE to examine cell growth, 
morphology and viability compared to untreated cells. Morphology was observed 
using a light microscope and cells were photographed at 100 x magnification prior 
to cell count using the Trypan blue exclusion method. Both manual and 
automated cell count were carried out in order to compare cell count and viability 
across all experiments conducted.  
3.2.1 Cell growth and morphology 
Figure 3.3 depicts the morphology of cells when untreated and exposed at 0.1 or 
1 mg/mL GTE. HepG2 cells treated with 0.1 mg/mL GTE appeared to have no 
profound morphological changes compared to the control. Cell density was 
roughly equal across all treatments, but there were morphological changes after 
24 h exposure to 1 mg/mL GTE. There was minor aggregation of cells as the GTE 
concentration increased compared to the control which affected the overall 
appearance of the cells. The cells began to lose their slightly elongated shape and 
became more spherical in 1 mg/mL GTE-treated cells. The most noticeable 
change was the brown staining of cells exposed to 1 mg/mL GTE, whereas the 






















Figure 3.3. Light microscope photographs of (a) untreated, (b) 0.1 and (c) 1 
mg/mL GTE-treated HepG2 hepatocellular cells after 24 h at 100 x 























3.2.2 Manual vs semi-automated cell counting 
Table 3.6 depicts the average total cell count, viability and their associated relative 
standard deviation (RSD) for the 0.1 mg/mL exposure data set using both manual 
and semi-automated cell counting. Using the manual cell count method, the 
average total cell count for the control was 2.62 x 106 (± 1.42 x 106) cells/mL, a 
22% increase from cells treated with 0.1 mg/mL GTE (2.04 x 106 ± 2.7 x 105 
cells/mL). However, the RSD for the total cell count was substantially higher for 
the control than for 0.1 mg/mL GTE exposure, with RSDs of 54.35% and 13.44% 
for the control and 0.1 mg/mL data, respectively. The average cell viability for the 
control was 95% (± 2.83), whereas it decreased by 2.25% to 92.75% (± 4.35) upon 
exposure to 0.1 mg/mL GTE. Average cell viability showed a considerably lower 
RSD compared to the average total cell count, with RSDs of 2.98% and 4.69% for 
the control and 0.1 mg/mL exposure data, respectively.  
Average total cell count using the semi-automated method detected fewer cells 
compared to the manual method, where the average total cell count was found to 
be 9.38 x 105 (± 1.89 x 105) cells/mL for the control and 9.7 x 105 (± 1.58 x 105) 
cells/mL upon 0.1 mg/mL GTE exposure. In contrast to the manual method, the 
semi-automated method detected 3.3% greater number of cells in 0.1 mg/mL 
GTE-exposed cells compared to the control. Statistical significance was observed 
between the manual and semi-automated methods for the GTE (p < 0.001), but 
not between the controls (p > 0.05). This was similar for the average cell viability, 
where 0.1 mg/mL GTE-exposed cells experienced a 1.25% increase in viability 
(96.5 ± 3.11% and 97.75 ± 1.50% for the control and 0.1 mg/mL GTE-exposed 




significance between the manual and semi-automated methods (p > 0.05). The 
semi-automated method had a considerably lower RSD in both the total cell count 
and viability as a result. 
Table 3.7 shows the average total cell count, viability and RSD between the 
control and 1 mg/mL GTE-exposed cells using both manual and semi-automated 
cell counting. For the manual method, the average total cell count was 6.0 x 105 
(± 2.8 x 105) cells/mL and 1.08 x 106 (± 6.7 x 105) cells/mL for the control and 1 
mg/mL GTE-exposed cells, respectively. The RSD in both treatments was 
substantially higher with RSDs of 47.31% and 62.49%, respectively. This was 
slightly lowered using the semi-automated method, with the RSDs being 44.03% 
and 38.85% for the control and 1 mg/mL GTE-exposed cells, respectively. 
Significant differences were observed in control and GTE-treated cells between 
automatic and manual cell counting (p < 0.020 and p < 0.001, respectively). Cell 
viability was much lower in the manual method compared to the semi-automated 
method, with a difference of 18.08% for the control and 29.34% for GTE-exposed 
cells. This was reflected in the RSD, which decreased by 12.92% and 24.61% in 
control and GTE-exposed cells, respectively. Significant differences were observed 
in control and GTE-treated cells between automatic and manual cell counting for 
viability (p < 0.001). 
Upon comparison between manual and the semi-automated methods at both 
treated concentrated, the RSDs were generally higher and therefore showed less 
accuracy in the manual method. The semi-automated cell count data was more 





Table 3.6. Average total cell count, cell viability and associated RSD for both 
manual and semi-automated cell count techniques for 0.1 mg/mL exposure data. 
Total cell count and cell viability data is represented as the mean ± standard 
deviation, and RSD represented as percentage. N = 4 for each treatment. 
 
 
Table 3.7. Average total cell count, cell viability and associated RSD for both 
manual and semi-automated cell count techniques for 1 mg/mL exposure data. 
Total cell count and cell viability data is represented as the mean ± standard 





Total cell count 
(106 cells/mL) 
RSD (%) Cell viability (%) RSD (%) 
Control 2.62 ± 1.42 54.35 95.00 ± 2.83 2.98 
0.1 mg/mL 2.04 ± 0.27 13.44 92.75 ± 4.35 4.69 
SEMI-AUTOMATED 
 Total cell count 
(105 cells/mL) 
RSD (%) Cell viability (%) RSD (%) 
Control 9.38 ± 1.89 20.13 96.50 ± 3.11 3.22 
0.1 mg/mL 9.70 ± 1.58 16.28 97.75 ± 1.50 1.53 
MANUAL 
 
Total cell count 
(106 cells/mL) 
RSD (%) Cell viability (%) RSD (%) 
Control 0.60 ± 0.28 47.31 68.75 ± 14.61 21.25 
1 mg/mL 1.08 ± 0.67 62.49 49.58 ± 17.85 36.00 
SEMI-AUTOMATED 
 Total cell count 
(105 cells/mL) 
RSD (%) Cell viability (%) RSD (%) 
Control 3.64 ± 1.60 44.03 86.83 ± 7.23 8.33 




3.2.3 Cell counts and cell viability 
Figure 3.4 depicts the mean cell viability for untreated and GTE-treated cells as 
determined by the Trypan blue exclusion method. Viability of cells treated with 
0.1 mg/mL GTE increased by 1.30% (101.30 ± 1.50%) after 24 h exposure 
compared to untreated cells (100 ± 3.11%), which was not statistically significant 
(p > 0.05). Figure 3.4b shows that the viability of cells treated with 1 mg/mL GTE 
decreased by 9.11% (90.88 ± 9.00%) compared to untreated cells (100 ± 7.23%), a 
statistically significant difference as determined by Student’s t-test (p < 0.027). 
Figure 3.5 shows the mean total cell count (cells/mL). As per Figure 3.5a, the 
mean total cell count for untreated cells and cells treated with 0.1 mg/mL GTE  
was 9.38 x 105 (± 1.89 x 105) and 9.70 x 105 (± 1.58 x 105) cells/mL, respectively. 
With only a difference of 3.20 x 104 cells/mL (3.35%), there was no observable 
difference, nor was it statistically significant (p > 0.05). Figure 3.5b shows the 
mean total cell count decreasing from 3.64 x 105 cells/mL (± 1.60 x 105) to 2.63 x 
105 cells/mL (± 1.02 x 105) when treated with 1 mg/mL GTE, a difference of 1.01 
x 105 cells/mL (27.7%). Although visually different, Student’s t-test confirmed that 































Figure 3.4. Mean cell viability (%) for untreated and GTE-treated HepG2 cells after 
24 h exposure to (a) 0.1 (n = 4) and (b) 1 mg/mL GTE (n = 12), as determined by 
Trypan blue exclusion. All values are expressed as the percentage of the control ± 
standard deviation. * indicates significant difference (p < 0.05) between untreated 
and GTE-treated cells. 
 
Figure 3.5. Average cell viability (%) for untreated and GTE-treated HepG2 cells 
after 24 h exposure to (a) 0.1 (n = 4) and (b) at 1 mg/mL GTE (n = 12), as determined 















































































































Figure 3.5. Mean total cell count (cells/mL) for untreated and GTE-treated HepG2 
cells after 24 h exposure to (a) 0.1 (n = 4) and (b) 1 mg/mL GTE (n = 12), as 






3.2.4 MTT assay 
To determine the effect of CH, EC, EGC, EGCG and GTE concentration on cell 
viability, human hepatocellular HepG2 cells were cultured in 96-well plates at a 
range of concentrations for GTE (0.1, 0.5 and 1 mg/mL) and catechin standards 
(25, 50 and 100 µM) and cell viability measured using an MTT assay. Viable cells 
use its intracellular NAD(P)H-dependent oxidoreductases to convert MTT 
(yellow) to formazan (blue/purple) as seen in Figure 2.2. The colour intensity was 
measured at 570 nm and is directly proportional to cell viability. Statistical 
analysis was conducted using a one-way analysis of variance (ANOVA) with 
Bonferroni post-hoc testing to compare each concentration to the control. 
Figure 3.6 shows the mean cell viability of untreated, CH, EC, EGC, EGCG and 
GTE-treated HepG2 cells after 24 h exposure. In general, the viability increased 
above the control with the exception of cells exposed to 50 and 100 µM EGC.  
EGCG treatment at all concentrations showed a linear increase in cell viability as 
concentration increased. Cell viability increased by 9.57% (± 7.26; p < 0.001), 
14.04% (± 5.36; p < 0.001) and 17.50% (± 6.35; p < 0.013) compared to the control 
when treated with 25, 50 and 100 µM, respectively. Similar to EGCG, EC-treated 
cells also followed a positive linear relationship between cell viability and EC 
concentration. Compared to untreated cells, the cell viability increased by 1.86% 
(± 1.64), 3.77% (± 2.92) and 4.99% (± 2.05) when cells were exposed to 25, 50 
and 100 µM, respectively. Although the difference in cell viability was less 
pronounced than EGCG treatment, there were significant differences between the 
control and 50 (p < 0.004) and 100 µM (p < 0.001) EC treatments. Treatment at 




Cells treated with EGC followed a different trend compared to EGCG and EC. 
25 µM EGC treatment had a very similar cell viability (0.12% ± 3.87) compared 
to the control, but the cell viability reduced to 94.28% (± 4.71) at 50 µM, a 
significant decrease of 5.72% (p < 0.015). The cell viability increased to 97.99% (± 
6.75) at 100 µM, with no statistical significance observed (p > 0.05). Cells treated 
with various concentrations of CH had similar cell viability and varied by 0.91-
2.52% compared to the control. The cell viability increased to 100.91% ± 0.039 at 
25 µM CH from the control and reached its highest cell viability at 50 µM (102.52% 
± 2.17). However, a one-way ANOVA determined there was no significance 
between the 50 µM CH and the control (p > 0.05). The cell viability decreased to 
101.73% ± 3.59 at 100 µM CH. Overall, CH did not have any statistically 
significant changes when compared to the control.  
Cells treated with various concentrations of GTE demonstrated significant 
changes compared to the control. Cell viability increased from 100% ± 5.23 to 
120.42% ± 6.30 after exposure to 0.1 mg/mL GTE (p < 0.001). The cell viability 
plateaued after exposure to 0.5 (p < 0.001) and 1 mg/mL GTE (p < 0.001) and 






















Figure 3.6. Cell viability (%) of (a) EGCG, (b) EGC, (c) EC, (d) CH and (e) GTE-treated 
HepG2 cells at different concentrations (n =12) after 24 h exposure. Data is expressed as the 
percentage from the control ± standard deviation. Statistical significance was tested using a 
one-way ANOVA with Bonferroni post-hoc testing as indicated by * = p < 0.05; ** = p < 0.01; 


































































































































































3.2.5 Metabolomic analysis 
To analyse biochemical changes that occur in GTE-treated HepG2 cells, 
untargeted metabolomic analysis was conducted using GC-MS. Differences in 
intracellular metabolites were analysed at two different GTE concentrations of 0.1 
and 1 mg/mL with ten replicates of control and GTE-treated cells after 24 h 
exposure.  
Intracellular metabolites were extracted from the cells and analysed through GC-
MS to indicate whether the levels of different metabolites changed with GTE 
exposure and, consequently, if the same biochemical pathways were affected at 
different doses. All data was normalised to the internal standard (D-13C6-sorbitol) 
and cell count. As previously mentioned, difficulties with cell counts for the 1 
mg/mL exposures prevented data being normalised to the cell counts. All data 
was log10-transformed and mean-centered prior to PCA and PLS-DA analysis. 
The metabolites were identified through comparing mass spectra and retention 
times to the in-house library and NIST database (v2.3). Metabolite classification 
was based on the criteria outlined in Table 2.2. 
3.2.5.1  1 mg/mL exposure 
Figure 3.7 shows the PCA scores plot for intracellular metabolites found in ≥ 75% 
of replicates for cells exposed to 1 mg/mL GTE for 24 h. GTE-treated cells (red) 
are clearly separated from the untreated cells (blue) and loosely clustered along 
PC-1. PC-1 explained 19% of the variance and was the major principal component 
(PC) that explained variance between GTE-treated and untreated cells. Although 




variance between untreated and GTE-treated cells. Figure 3.8b shows the loadings 
plot for each metabolite and was referred to for identification of each metabolite. 
Figure 3.8a shows the PLS-DA scores plot. Factor-1 explained 19% of the variance 
of the x variables (the independent variable, i.e. the metabolomic data) identified 
as the metabolite peak areas from GC-MS analysis. Factor-1 also explained 86% 
of the variance of the y variable (dependent variable, i.e. the treatment groups), 
identified as the two sample sets (untreated and GTE-treated cells). It can be 
assumed that Factor-1 represented the most variance due to the influence of GTE 
on the metabolome. In contrast, 7% of the variance was explained in both the x 
and y variables for Factor-2, and therefore it can be assumed that it experienced 
equal variance in both variables. After PCA and PLS-DA analysis, the loadings 
for each data point were exported and metabolites identified via the in-house 
library and the NIST mass spectral database to investigate the fold change from 
the control. 
Table 3.8 indicates the fold changes of the normalised peak area for each 
metabolite identified as contributing most to the variance identified from PLS-DA 
analysis. All metabolites were listed according to their compound class (amino 
acid, carboxylic acid, oxoacid, carbohydrate, nucleic acid, fatty acid and ‘other’). 
Some metabolites were excluded due to duplication or a compound identified to 
be a part of the column, making the total number of important metabolites 27. 14 
of the 27 metabolites were able to be fully identified (≥ 20% probability, Match 
and R.Match ≥ 700) with a further five metabolites putatively identified. 25 of the 
27 metabolites (93%) were decreased and two (7%) were increased in GTE-treated 
cells compared to the control cells. The data showed an overall decrease in all 




oxoacids. Unidentified sugar_32.270 had the largest increase of 2.224-fold (p < 
0.002) and unknown_28.850 having the largest decrease of 0.063-fold (p < 0.001). 
The majority of the metabolites appear to be amino acids, which were decreased 
in all instances. Almost all of the identified amino acids had a significant decrease 
in the mean peak area (p < 0.001), with the exception of L-cysteine (p > 0.05). All 
identified carboxylic acids, 1,2-benzenediol (p < 0.004) and unidentified 
carboxylic acid_22.627 (p < 0.001), had a fold decrease compared to the control 
and showed significant difference between the means. The oxoacids also had a 
fold decrease and were significant (p < 0.001). Although a fold decrease occurred, 
the nucleic acids and fatty acids did not have a significant difference (p > 0.05). 4 
of the 9 metabolites that could not be classified were significantly different, with 
fluoranthene and unknown_28.850 being the most significant (p < 0.001), 





Figure 3.7. Principal component analysis scores plot representing the metabolites 
contributing most to the variance after 24 h exposure to 1 mg/mL GTE. Grouping of 
sample sets is represented by coloured ovals (blue = control; red = GTE-treated). N = 10 





Figure 3.8. Partial least squares-discriminant analysis scores (a) and loadings plots (b) 
representing the metabolites contributing most to the variance after 24 h exposure to 1 
mg/mL GTE. Grouping of sample sets is represented by coloured ovals (blue = control; 






Table 3.8. Metabolites identified by PLS-DA contributing most to the variance 
from the control and their corresponding fold change upon exposure to 1 mg/mL 
GTE. Red arrows represent fold decrease observed between GTE-treated (n = 10) 
and control (n = 10) cells, and green arrows represent a fold increase. Statistical 
significance was observed using Student’s t-test as indicated by * = p < 0.05; ** = 
p < 0.01; *** = p < 0.001. † indicates putatively identified metabolites. 















Unidentified carboxylic acid_22.627 0.072*** 
Oxoacids 
Phosphoric acid 0.205*** 
Citric acid 0.207*** 
Carbohydrates 




Unidentified fatty acid_32.377 0.765 
Other metabolites 







Unidentified alcohol_45.467 1.142 






3.2.5.2  0.1 mg/mL exposure 
Figure 3.9 shows the PCA scores plot for untreated and 0.1 mg/mL GTE-treated 
cells following 24 h exposure. The cluster of GTE-treated cells (red) are more 
tightly clustered than the untreated cells (blue). PC-1 explained 18% of the 
variance experienced between untreated and GTE-treated cells, while PC-2 
explained 13% of the variance. Figure 3.10a shows the PLS-DA scores plot. 
Factor-1 explained 10% of the variance in the x variables. It also explained 60% 
of the variance in the y variables, and therefore can be assumed that Factor-1 
represented the most variance due to the influence of GTE on the metabolome. 
For Factor-2, the x and y variables explained 11% and 16% of the variance, 
respectively. Figure 3.10b shows the loadings plot for each metabolite and was 
referred to for identification of each metabolite. 
Table 3.9 shows the fold changes of the normalised peak area for each identified 
metabolite contributing most to the variance identified from PLS-DA analysis  
when exposed to 0.1 mg/mL GTE. One control sample was removed from 
analysis due to derivatisation or injection failure. The total number of detected 
metabolites was 21, of which half were increased. In total, 5 metabolites could be 




putatively identified. Two metabolites, unidentified fatty acid_32.275 (p < 0.031) 
and  unknown_26.695 (p < 0.009), had the most substantial difference compared 
to the control. Other metabolites had a smaller fold changes and were not 
statistically significant. 
The majority of metabolites appeared to be amino acids which experienced a 
mixture of fold increase and decrease but had no significant difference compared 
to the control (p > 0.05). This contrasts with 1 mg/mL exposure, where almost all 
amino acids experienced a significant fold decrease compared to the control. 
There were also considerable differences in the amino acids identified. Compared 
to 1 mg/mL GTE exposure, where 11 different amino acids were identified, only 
3 amino acids were identified with 0.1 mg/mL GTE exposure (and 3 unidentified). 
One amino acid, L-isoleucine, was similar among the different treatment 
concentrations. 3 carbohydrates and 4 fatty acids were detected in 0.1 mg/mL 
exposure compared to 1 mg/mL exposure, but no significant differences were 
found. Neither carboxylic acids, oxoacids nor nucleic acids were detected in this 




































Figure 3.9. Principal component analysis scores plots representing the metabolites 
contributing most to the variance after 24 h exposure to 0.1 mg/mL GTE. Grouping 
of sample sets is represented by coloured ovals (blue = control; red = GTE-treated). 






Figure 3.10. Partial least squares-discriminant analysis scores (a) and loadings plots 
(b) representing the metabolites contributing most to the variance after 24 h exposure 
to 0.1 mg/mL GTE. Grouping of sample sets is represented by coloured ovals (blue = 






Table 3.9. Metabolites identified by PLS-DA as contributing most to the variance 
from the control and their corresponding fold change upon exposure to 0.1 
mg/mL GTE. Red arrows represent a fold decrease observed between GTE-
treated (n = 10) and control (n = 9) cells, and green arrows represent a fold increase. 
Statistical significance was observed using Student’s t-test as indicated by * = p < 
0.05; ** = p < 0.01. † indicates putatively identified metabolites. 





Unidentified amino acid_20.437 0.924 
Unidentified amino acid_28.018 1.409 
Unidentified amino acid_28.548 1.161 
Fatty acids 
Decanoic acid 1.166 
Unidentified fatty acid_29.260 0.946 
Unidentified fatty acid_32.275 0.942* 
Carbohydrates 
Unidentified sugar_32.257 1.021 
Unidentified sugar_39.198 1.090 




Unidentified organic compound_27.405 0.980 
Other metabolites 












4.1 Analysis of GTE composition 
4.1.1 GTE metabolite analysis 
Green tea extract (GTE) is one of the most popular beverages in the world, and is 
extracted and concentrated for its use as a herbal supplement. Metabolomic 
analysis was conducted on a variety of GTE and GTE-containing products to 
understand the biochemical similarities between these products and how 
differences could impact liver health. The packaging of the product used in this 
study includes an advisory and warning label indicating the demographic for 
consumption and the origin of the ingredients. An AUST R or AUST L number 
is absent from the packaging, indicating that this particular GTE product is not 
listed in the ARTG and is likely to be regulated as a food product instead of a 
herbal medicine. All food products are regulated in accordance to the Australia 
New Zealand Food Standards Code, also known as the Food Standards Code, by 
their respective state or territory.96 The Food Standards Code states that a product 
advertised as a formulated supplementary sports food requires a nutrition 
information panel on the packaging.96 An initial concern was the lack of 
macromolecule nutritional information on the packaging, as studies have detected 
the presence of sugars and amino acids.97 However, the small concentrations 
detected in GTE may be the reason for the lack of nutritional information on the 
packaging. Therefore, according to the Food Standards Code, the product seems 




Two fatty acids, palmitic and stearic acid, were detected in each GTE sample. 
Unsaturated fatty acids are commonly found in plant extracts and can be oxidised 
to volatile compounds that have characteristic aromas during the manufacturing 
process, such as 1-penten-3-ol and n-nonanal.97 Alcohols are volatile compounds 
that contribute to green, floral, lemon, fresh aromas in green tea.98 The putatively 
identified compounds, 3-methyl-4-oxo-2-pentenoic acid, ethanol-2-(methylamino), 
N-trifluoracetyl, O-tert-butyldimethylsilyl and 4-ethyl-2-octanol may be chemical 
derivatives of such volatile compounds. The presence of a sugar within GTE is 
also corroborated by other studies.97,99 The presence of free sugars are highly 
correlated with inducing the formation of aromatic alcohols in green tea.97 
Galactose oxime, the chemical derivative of galactose, was putatively identified 
within the GTE samples and other studies have identified glucose, fructose and 
sucrose in GTE.99,100  
It is possible that the fatty acids and sugars may contribute to hepatoprotective 
effects of GTE. Fatty acids are involved in ATP production through their 
catabolism by β-oxidation to form acetyl CoA, an intermediate within the TCA 
cycle. It has recently been suggested that supplementation with GTE induces 
peroxisome proliferator-activated receptor (PPAR) genes involved in the up-
regulation of β-oxidation in the liver.101 The presence of fatty acids in GTE may 
contribute to increased β-oxidation for hepatoprotective effects, such as fatty liver 
disease associated with a high fat diet.101 
Other studies have identified an array of amino acids in GTE,99,100 which were not 
identified in this study. This is possibly due to the high replicate percentage that 




used in the derivatisation process. However, it may also be due to the extraction 
process used in this study. Changes in the extraction method, time of extraction 
and extraction temperature for the manufacturing of GTE have been shown to 
vary the amino acid concentration.102 Conventional methods of tea extraction use 
heated distilled water, whereas this study used methanol. Using methanol has the 
advantage of extracting more polar metabolites, but a two-phase system (such as 
chloroform and water) may be a more efficient method for detecting metabolites 
that were not extracted.103  
1-piperidinecarboxyaldehyde is a piperidine, a hydrogenised pyridine, and present 
in some plants82 and is known to induce toxicity at acute doses.104  It is likely that 
this metabolite is the result of the chemical derivatisation of pyridine before GC-
MS analysis. However, it has also been found to be an organic leachable, 
compounds that are able to migrate from packaging and into the product and are 
found in trace amounts. As the compound is highly soluble and is frequently 
observed as an extractable, it increases the risk of harm to an individual.105 The 
frequency with which it was observed in these samples suggests that, if it is not 
derived from the sample preparation process, it may be commonly in GTE 
products. As the metabolite is known to induce acute toxicity,104 further research 
should focus on deducing the toxicity of this compound at chronic doses within 
GTE products.  
Many of the detected metabolites either have no particular function within GTE 
or were derivatives of chemicals used to derivatise metabolites. This study used 
MSTFA to derivatise metabolites. Although a popular silylation reagent in plant 




MS analysis.103 The high replicate percentage (≥ 75%) chosen for this study may 
have affected the true number of metabolites detected in this sample set. 
Confidence in the identification of most of these metabolites is low, and therefore 
the aim of identifying and characterising the biochemical components of 
commercial GTE products was partially fulfilled. Identifying these will need 
further elucidation to understand the pathophysiology of GTE hepatotoxicity. 
Limitations in metabolite identification are further discussed in section 4.3. 
4.1.2 Variation in relative catechin levels of GTE products 
Following on from previous studies into catechin-related hepatotoxicity from 
GTE,38,51,65 analysis of the relative catechin levels was conducted between different 
GTE and GTE-containing products. Catechins were not detected in GTE 69, 289, 
295 or 300, with three of these samples being GTE-containing products. GTE 305 
consistently had the highest relative levels of EC, EGC and EGCG, with the most 
significant being a 10.31-fold higher level of EC compared to the NIST SRM. In 
contrast, GTE 248 had the lowest relative levels, with the most significant being a 
0.17-fold lower level of EGC. The GTE sample purchased for this study had a 
variety of relative levels, with the most significant being a 9.99-fold higher level in 
EC compared to the NIST SRM. 
The most interesting result was from the 10-fold higher level of EC in both GTE 
305 and the GTE sample purchased for this study, both of which were significant. 
EC has been suggested to have the least toxic effect on hepatocytes.38 Galati et al. 
suggested that the LD50 for rat hepatocytes was over 10,000 µM,
38 the equivalent 
of approximately 3 mg/mL. As EC comprises only 0.8% of the green tea 




would require a higher concentration to induce a hepatotoxic response. The 10-
fold higher level of EC for GTE 305 and the purchased sample would probably 
not be enough to induce a hepatotoxic response from EC alone, but the variation 
in levels between samples is concerning. 
Relative levels of EGC were generally lower in all products, except GTE 305. The 
most significantly lower relative levels were in GTE 245, 248, 304 and 321, 
ranging from 0.083 to 0.193-fold lower. The LD50 for EGC has been suggested to 
be 3000 µM,38 equivalent to approximately 0.9 mg/mL. As EGC comprises 
approximately 6% of the total composition in green tea (approximately 0.057 
mg/mL in a 1 mg/mL sample),68 it is not likely that these GTE samples would 
induce a hepatotoxic response from EGC alone, similar to EC. The relatively low 
levels of EC and EGC in the purchased GTE product suggests that these catechins 
may not be responsible for inducing hepatotoxicity in HepG2 cells.  
EGCG has been at the centre of hepatotoxicity studies for some time and has been 
regarded as the most toxic of all catechins.38,51,65 In vitro studies using primary rat 
hepatocytes have shown hepatotoxicity at a variety of concentrations at seeding 
densities similar to those used in this study, ranging from 10 - 200 µM (0.005 - 0.09 
mg/mL).38,65 The composition of EGCG is approximately 5% of the brewed 
amount of green tea,68 and is much more concentrated in GTE, comprising 
approximately 17% of the composition.52 Therefore, it is likely that the GTE 
samples that showed the highest relative levels of EGCG, GTE 239, 305 and the 
purchased sample for this study, may induce a more acute hepatotoxic response 




The expected proportions of each catechin are only estimates extracted from the 
literature. As the use of untargeted metabolomics is only a semi-quantitative 
technique,106 it prevents the quantification of each catechin from the GTE samples. 
The data did show that there was considerable variation among catechins levels, 
suggesting that environmental factors and extraction techniques can change the 
composition of GTE and its detected metabolites.47,48,103 The potential for GTE-
induced hepatotoxicity for the purchased product used for this study is 
considerable, and the data brings into question the safety regulations that are 
associated with the product.  
4.2 Analysis of GTE exposure 
4.2.1 Cell growth and morphology 
Growth and morphological changes in HepG2 cells were observed under a light 
microscope. Cells appeared to become spherical and brown staining upon 
exposure to 1 mg/mL GTE. Aggregation was not noted as a significant change in 
morphology as HepG2 cells are a proliferative cell line and therefore grow in 
clustered 3-dimensional (3D) structures on a monolayer. There are no current 
studies with insight on morphological changes in GTE-treated HepG2 cells, but 
other products high in polyphenols presented similar observations of round 
shaping of HepG2 cells, such as exposure to grape pomace extract.107 Jimenez-
Lopez and Cederbaum showed that HepG2 cells overexpressing CYP2E1 treated 
with arachidonic acid and iron experienced rounding of cells, and showed EGCG 
resolved this phenomenon.108 The rounding of cells, blebbing (protrusion of cell 
membrane) and DNA fragmentation are hallmarks of apoptosis.109 Therefore, it is 




transmission electron microscopy (TEM) may be a beneficial tool to further 
observe the presence of apoptosis in GTE hepatotoxicity, as demonstrated in a 
similar study.110  
The most interesting change in morphology was the brown staining of the cells, 
which was also observed at a macroscopic level. The polyphenol subsets, 
theaflavins and thearubigins, are a product of oxidised catechins catalysed by 
endogenous oxidase enzymes during the fermentation of green to black tea to 
produce the characteristic reddish-brown pigment found in black tea.43,111 However, 
these endogenous oxidases are heat-inactivated during production of green tea and 
therefore cannot formed the pigmented molecules.111 Another subset of 
polyphenols, the tannins, may be a plausible cause for the staining of cells.  
Tannins are soluble molecules that range from yellow to brown pigments and have 
the ability to complex with multiple macromolecules such as proteins, starch and 
cellulose.112 Tannins are separated into hydrolysable and condensed tannins 
(proanthocyanidins), of which proanthocyanidins play defensive roles against 
pathogens in many vascular plants.113 Therefore, it may be possible that the 
proanthocyanidins dissolved within the medium and complexed with the 
phospholipids and proteins on the cell membrane of the HepG2 cells to cause 
reddish-brown staining. Along with observing changes in nuclear morphology, 
TEM would have confirmed the presence of tannins interacting with the cell 
membrane, as previously used in a similar study.113 
As this project was conducted using a hepatocellular carcinoma cell line, there 
were dissimilar morphological variations observed in liver biopsies in case studies 




degeneration, individual cell necrosis, lobular collapse and disorganised 
architecture.60-63 This study found a change in cell architecture to be the only 
similarities in an in vivo setting. It is known that the extrapolation from in vitro 
hepatotoxicity to in vivo models is a challenge among researchers. New 
technologies, such as 3D scaffolds or sheets, may improve extrapolation by 
emulating the lobule structure of normal liver tissue.114,115 
4.2.2 Differences in manual and semi-automated cell counting 
This study compared the use of a microscope haemocytometer slide and a semi- 
automated cell counter on the reproducibility on total cell count and viability data 
using the Trypan blue exclusion method. This was determined by calculating the 
percentage RSD, which determines the precision of the data set. The RSD was 
generally higher in the manual method compared to the semi-automated method, 
indicating the data was varied and less precise. 
Cell viability and concentration within cell lines is paramount in the 
reproducibility of subculturing.116 Manual cell counting with a haemocytometer 
has been the most widely used technique, and whilst it is an inexpensive technique 
it is prone to human error. This can include uneven distribution of cells, high cell 
densities, and different human perceptions of cell categorisation.116 As manual cell 
counting can be a time-consuming task, especially for large cohort studies, Trypan 
blue can become toxic to cells over time and change the morphology of the cell, 
causing the influx of Trypan blue and identifying it as a dead cell.117 This may have 
contributed to the consistently lower cell viability in the manual method compared 
to the semi-automated method. Although, a haemocytometer is highly 




interpretation118 and therefore reproducibility is subject to the user’s degree of 
experience. 
Semi-automated methods do not come without limitations. The frequency of 
misclassifying live and dead cells is higher compared the manual methods, such 
as with cell clumps, which can decrease the accuracy and percentage recovery.118 
This may explain the consistently lower total cell counts in the semi-automated 
method compared to manual methods. Semi-automated methods require pipetting 
which introduces the possibility of uneven distribution of cells.116 Therefore, semi-
automated methods may not reflect the true total cell count. 
4.2.3 Cell counts and viability 
The results from Trypan blue exclusion showed that there was a significant 
decrease in cells exposed to 1 mg/mL GTE, and no significant changes observed 
when exposed to 0.1 mg/mL GTE. There were no significant changes in total cell 
count (cells/mL). The results show that there was a dose-dependent change in cell 
viability and total cell count. 
Similar occurrences of decreased cell viability or survivability have been 
demonstrated in other studies involving GTE or catechins. Kucera et al. observed 
a decline in cell viability and increase in MMP in primary rat hepatocytes over 24 
h when exposed to 10, 30 and 100 µmol/L EGCG65 doses 20 x lower than 
observed by Galati et al.38 Lambert et al. conducted a closely related study showing 
a dose-dependent decrease in murine survivability upon exposure to EGCG, 
reaching up to 85% mortality.51 However, a study involving sub-acute toxic doses 




adverse pathological effects on mouse liver,119 supported by another study at 1250, 
2500 and 5000 mg/kg GTE.120 Hepatotoxicity appears to be more severe in cases 
of pure catechin extract compared to GTE in both in vivo and in vitro techniques. 
However, this study is the first to find a significant change in cell viability using in 
vitro techniques. 
The Trypan blue exclusion results are in direct contrast to the cell viability 
observed in the MTT assay. The results from the MTT assay showed that the 
viability increased in almost all instances compared to untreated cells with the 
exception of 50 µM EC. The MTT assay was attempted twice as the growth 
medium became too dark during incubation, which can affect spectrophotometer 
readings. The second attempt involved removing the spent medium and adding 
new medium prior to adding dye solution to reduce inaccurate absorbance 
readings, but may have caused loss of cells that did not adhere to the culture plate. 
The MTT assay has an advantage over the Trypan blue exclusion method in that 
it is more sensitive to detecting impairment of cell function, requires less labour 
and is quicker. However, recent reports have shown that free thiols and flavonoids 
in some herbal extracts may be involved in the reduction of MTT to 
formazan.121,122 Other compounds that may interfere include GSH, ascorbic acid 
(vitamin C) and retinol (vitamin A1).
123,124 Wang et al. also showed an 
underestimation in the antiproliferative activity of EGCG using an MTT assay 
over a 24h period.125 Although MTT assays are considered the gold standard in 
cell viability testing, inconsistencies between the Trypan blue exclusion method 
and the MTT assay suggests that GTE, catechins and other phytochemicals may 
interfere with formazan reduction. Future studies in GTE hepatotoxicity may 




adenosine triphosphate (ATP) or DNA assays, which have been shown to 
measure the true anti-proliferative action in green tea polyphenols.125 
Trypsinisation is a commonly used procedure for detachment of cells from culture 
flasks and is arguably one of the best procedures for minimising cell damage and 
false negatives.126 However, cells treated with 1 mg/mL GTE experienced 
difficulty in detachment from the culture plate when treated with PBS and 0.25% 
trypsin-EDTA. The experiment was repeated with adjustment to the amount of 
trypsin and incubation time, but with no improvement. This may be due to 
insufficient washing of cells with PBS, where it is known that calcium (Ca2+) and 
magnesium (Mg2+) in serum can cause cells to adhere together and to the culture 
flask.116 However, studies have claimed that tea polyphenols, such as EGCG, have 
a non-competitive inhibitory effect on trypsin at a concentration of 0.05 mg/mL 
through conformational changes in the secondary structure of the protein.127-129 
Although not relevant in hepatotoxicity, this could be an additional biochemical 
pathway affected by GTE in the small intestine. Future studies may need 
adjustment to a higher concentration of trypsin and amount of PBS washes used.  
4.2.4 Biochemical responses to green tea extract 
Metabolomic analysis of GTE-treated HepG2 cells was conducted at two different 
concentrations (0.1 and 1 mg/mL) to establish possible biochemical pathways of 
GTE hepatotoxicity. Metabolites in cells exposed to 1 mg/mL GTE generally 
experienced a decrease in fold change the majority of the time, with amino acids 
being the most commonly identified class of compounds. Other compound classes 
detected include carboxylic acids, oxoacids, carbohydrates, nucleic and fatty acids. 




change in response to exposure. This suggests that a change in GTE dosage may 
change the biochemical pathways affected, whether it be hepatotoxic or 
hepatoprotective effects. 
4.2.4.1  1 mg/mL exposure 
Amino acids 
Amino acids are essential in the biosynthesis of proteins, DNA and carbohydrates. 
All identified amino acids in this study experienced a fold decrease, suggesting 
that amino acids were being catabolised. L-glutamine experienced the most 
substantial fold decrease upon exposure to 1 mg/mL GTE. L-glutamine is the 
active form of glutamine and a non-essential amino acid which has a crucial role 
in many processes in the liver, such as GSH biosynthesis.  
GSH is an antioxidant used in many foods and supplements for protection against 
damaging oxidants. L-glutamine is converted to L-glutamic acid through the 
action of glutamine synthetase and combines with L-cysteine to form γ-
glutamylcysteine. In the presence of glycine and GSH synthetase, γ-
glutamylcysteine is then converted to GSH.82 HepG2 cells experienced a fold 
decrease in both L-glutamine, L-glutamic acid and L-cysteine (Table 3.8), 
suggesting the rapid metabolism of these amino acids and an increase in GSH 
synthesis in the presence of GTE. This ultimately suggests that GTE exposure may 
be accelerating the production of GSH to counteract pro-oxidants, supporting the 
hypothesis of oxidative stress as a possible biochemical pathway of GTE 
hepatotoxicity. This is consistent with other in vivo liver studies, where there was 
an increase in ROS and increase of GSH in the presence of high doses of 




production and GSH occur depending on dose.65,130 This further implies that GSH 
biosynthesis is a dose-dependent pathway for oxidative stress. This information 
potentiates the evidence of apoptosis occurring within the HepG2 cells; it is well-
established that increased ROS production can trigger apoptosis through many 
avenues, such as p53 and caspase activities.131 An intracellular ROS assay could 
be used to confirm high concentrations of ROS, in adjunct with TEM, to confirm 
apoptosis has occurred in GTE hepatotoxicity. 
In surplus, the branched chain amino acids (BCAAs) identified in this study (L-
isoleucine and L-valine) have been attributed to reduced oxidative stress132 and 
hepatic apoptosis in vivo.133 8-oxoguanine DNA glycosylase 1 (OGG1) gene, 
encoding an enzyme involved in the removal of 8-oxoguanine residues formed 
from exposure to ROS,134 was present in higher levels in liver injury-induced mice 
supplemented with BCAAs compared to healthy mice.132 This suggests a possible 
avenue of ROS production at both a metabolomic and genomic level, where the 
metabolism of BCAAs may increase the availability of OGG1 and induce DNA 
repair in oxidative stress-induced cells, as suggested in Table 3.8 showing a fold 
decrease in uracil. Interestingly, Sugiyama et al. found that a higher concentration 
of BCAAs had an inhibitory effect on the growth of HepG2 cells, whereas lower 
concentrations did not suppress growth.135 This contrasts with Figure 3.5, where 
the total cell count appeared to decrease upon exposure to 1 mg/mL GTE. This 
could indicate a dose-dependent response in cell growth, or the presence of other 
compounds contributing to stunted growth. 
In conjunction with the BCAAs, the identified aromatic amino acids (AAAs) (L-




The Fischer ratio explains the relationship between decreased BCAA and 
increased AAA plasma levels during liver injury, specifically concerning hepatic 
encephalopathy.136 This is thought to be due to increased BCAA catabolism within 
muscle cells and decreased AAA catabolism within the liver. As this study 
involved a hepatocellular carcinoma cell line and not an in vivo model, it limits the 
translatability to human models due to the absence of muscle cells, and therefore 
the study cannot follow the Fischer ratio. However, the Fischer ratio could aid in 
the diagnosis of systemic diseases such as hepatic encephalopathy upon exposure 
to GTE. As some GTE hepatotoxicity patients had experienced nervous system 
symptoms such as asterixis, it is valuable to further investigate the possibility of 
hepatic encephalopathy using in vivo models. 
A more ambiguous explanation for GTE hepatotoxicity is the involvement of L-
glutamine and L-glutamic acid in the urea cycle, also known as the ornithine cycle. 
L-glutamine is a precursor in the conversion of excess ammonia into urea within 
hepatic cells to allow excretion of highly-toxic ammonia.82 It is not known whether 
deficiency in L-glutamine and L-glutamic acid directly induces excess ammonia 
levels in the liver. It could be suggested that glutamine synthetase, an enzyme that 
catalyses the production of L-glutamine from L-glutamic acid and ammonia, 
cannot exert its function due to low levels of its precursor molecules to cause the 
accumulation of ammonia in liver cells. Accumulation of ammonia and its 
metabolites (e.g. carbamoyl phosphate) has been shown to directly cause liver 
injury in those with urea cycle disorders,137,138 but the exact mechanism has not 
been well characterised. It has also been suggested that ammonia exposure directly 
effects the mitochondrial RNA (mRNA) expression of antioxidant enzymes and 




Oxoacids and other metabolites 
Amino acids are not the only class compound that can contribute to GTE 
hepatotoxicity. The oxoacid phosphoric acid experienced a significant fold 
decrease upon exposure to 1 mg/mL GTE. Phosphoric acid is an important 
human metabolite appearing in many biological molecules, such as nucleic acids 
and glycerophospholipids. At a neutral pH, phosphoric acid can dissociate and 
exist as its conjugate bases dihydrogen phosphate and monohydrogen phosphate. 
A change in pH can form its conjugate base inorganic phosphate ion (Pi).
82 Pi is 
essential in the phosphorylation and dephosphorylation of cellular intermediates 
in metabolism, such as the phosphorylation of adenosine diphosphate (ADP) to 
ATP during oxidative phosphorylation. A deficiency in phosphoric acid may 
indicate high levels of Pi, suggesting that GTE may have changed the pH of the 
extracellular environment, causing a shift in the formation of Pi. This may cause 
uncoupling of oxidative phosphorylation from the ETC, influencing the MMP as 
seen by Kucera et al. and Galati et al.,38,65 causing ATP depletion. It has been 
suggested that a collapsed MMP may be due to GTE-induced apoptosis,38 but Pi 
deficiency may only be a minor contributor to this. 
An interesting metabolite that was putatively identified was 1,2-benzenediol, also 
known as pyrocatechol. It is formed in the metabolism of L-tyrosine, and both 
experienced a fold decrease. The reduced presence of pyrocatechol in GTE-
exposed cells is presumably due to stunted L-tyrosine metabolism, which reduces 
the production of intermediates involved in the TCA cycle,82 contributing to ATP 
depletion. This is also evident in the significant fold increase of unidentified 




oxidative stress was contributing to ATP depletion, amino acid levels would be 
expected to be present in higher amounts compared to untreated cells. This is 
presumably due to insufficient ATP production, required for the biosynthesis of 
amino acids from TCA cycle and glycolytic intermediates.140 
Analysis of the metabolic changes associated with 1 mg/mL GTE exposure 
suggests that the consumption of amino acids increases GSH and OGG1 
production, as well as the possible accumulation of ammonia and its metabolites 
and ATP depletion. This, in turn, may cause increased ROS production and 
oxidative stress-induced apoptosis. Additionally, a systemic effect of GTE 
hepatotoxicity has been suggested if disease progressed. A summary can be found 
in Figure 4.1. Further studies into characterising the biochemical pathways of 
GTE-induced hepatotoxicity may include GTE exposure at multiple time points 













































Figure 4.1. Schematic of proposed mechanism of GTE hepatotoxicity. Increased GSH is produced from the consumption of L-glutamine, L-
glutamic acid and L-cysteine to neutralise ROS. ROS can damage DNA and cause ATP depletion and apoptosis. Decreased phosphoric acid 
(H3PO4) increases Pi, uncoupling oxidative phosphorylation. Decreased L-isoleucine, valine and increased ammonia (NH3) may increase 
transcription of antioxidant and DNA repair enzymes. Decreased L-tyrosine and phenylalanine may cause systemic problems, such as hepatic 





4.2.4.2  0.1 mg/mL exposure 
Amino acids 
The composition of detected metabolites following exposure at 0.1 mg/mL was 
very different to what was observed upon 1 mg/mL GTE exposure. In the case of 
amino acids, the only identified amino acids were L-methionine, L-isoleucine and 
alanine, where three other amino acids were unable to be identified. L-isoleucine 
was the only amino acid in common with 1 mg/mL GTE exposure. According to 
statistical analyses, none of the fold changes were significant for amino acids.  
Similar to 1 mg/mL GTE exposure, L-isoleucine had a 0.884-fold decrease in the 
presence of 0.1 mg/mL GTE. This suggests that L-isoleucine was being 
metabolised, however at a much lesser extent than at a higher GTE concentration. 
This could be attributed to stimulation of OGG1 gene production for ROS 
protection, however, the small fold change indicates L-isoleucine, along with L-
methionine, was being metabolised for synthesis of TCA cycle intermediates for 
ATP production and protein synthesis.140 The minor fold decrease in alanine was 
presumably due to pyruvate synthesis for gluconeogenesis. This is corroborated by 
the presence of three unidentified sugars, of which two experienced a mild fold 
increase.  
Fatty acids and other metabolites 
The only identifiable fatty acid was decanoic acid, also known as capric acid.82 
One unidentified fatty acid, unidentified fatty acid_32.275, had a 0.942-fold 
decrease that was significant from untreated cells. Fatty acids are heavily involved 




dinucleotide (NADH) and flavin adenine dinucleotide (FADH2). These molecules 
are important intermediates or cofactors involved in the TCA cycle for ATP 
generation. The significant decrease in unidentified fatty acid_32.275 could be 
explained by the supplementation of fatty acids from the GTE, increasing β-
oxidation of fatty acids. As previously stated, GTE supplementation may also 
induce PPAR genes involved in the up-regulation of β-oxidation in the liver.101  
This is conflicted by Kim et al., who suggested that GTE increases the mRNA 
expression of various lipogenic enzymes within the liver and that lipolytic and β-
oxidation enzymes are not responsible for suppressing liver fat accumulation.141 
Another significant molecule was unknown_26.695, which experienced a 1.612-
fold increase. However, barriers in metabolite identification prevented the 
molecule being identified. There were organic compounds that were also found 
that were unique to this data set, however are not involved in biological processes 
within HepG2 cells. The limitations of metabolite identification are discussed in 
section 4.3.  
The limited number of significant fold changes upon exposure to 0.1 mg/mL GTE 
suggests that it does not have a significant effect on the biochemical pathways of 
hepatic cells at an acute dose.  Its effectiveness into improving liver health is still 
questioned, but a chronic dose may be attributed to improving overall liver health. 
It has been suggested that chronic doses of GTE may aid in fat reduction39 and 
anti-cancer effects.40,41 
4.3 Limitations and future study 
The study presented here is the first to look into the biochemical pathways 




limitation involving identification of the metabolites had the biggest impact on the 
outcomes. GC-MS has the advantage of having reproducible RTs compared to 
LC-MS, but the metabolome of different organisms and cell lines and the sheer 
number of metabolites within a database makes it difficult to identify the “correct” 
metabolite.89 The NIST database, in particular, is a non-specific library that 
encompasses a whole range of chemicals including metabolites.106 Therefore, 
compounds with a similar mass spectrum are more likely to be incorrectly 
identified. Scalbert et al. suggested that allowing a database to refine the search 
parameters for the spectral output, such as mammalian metabolites and toxins 
only, would improve the search results.89 This would aid in filtering out chemicals 
involved in derivatisation, thus increasing the statistical power of multivariate 
analysis of these metabolites. Future studies may require cross-referencing mass 
spectra with multiple databases to increase the confidence of correct metabolite 
identification. 
Beyond mass spectral databases, chromatographic techniques also contribute to 
limitations in metabolite identification. LC-MS, is valued for its sensitivity, ability 
to cover a wide range of compounds, giving the potential for comprehensive herbal 
medicine analysis, including challenging factors such as environment-dependent 
plant composition.142 LC-MS provides information about the exact mass of a 
monoisotopic form of a compound, whereas GC-MS relies on the chemical 
derivatisation of compounds to increase volatility during analysis, which can 
hinder compound identification. In silico fragmentation methods have been 
suggested to improve the identification of unknown metabolites by predicting the 
fragmentation and RT of a compound using GC techniques, which has shown to 




of a metabolite is dependent on assessing chemical structure by comparison to 
reference data (i.e. the use of chemical standards), for which NMR spectroscopy 
is highly specialised for.106 Therefore, future studies may include the use of NMR 
and targeted methods in order to confirm the presence and chemical structure of 
the metabolites identified in this study. 
As with any in vitro study, the translatability to in vivo or human subjects is difficult 
due to the variability in an organism’s metabolome. A single cell line can increase 
the reproducibility of metabolomic studies, but does not consider individual 
variability in metabolism and external factors, such as the coordination of other 
organs involved in metabolic pathways. The use of other hepatocellular carcinoma 
cell lines, such as HepaRG or primary hepatocytes, may aid in understanding the 
variability in the metabolome. 
From this study, apoptosis has been suggested to contribute to GTE hepatoxicity. 
As previously mentioned, the use of TEM may provide visual indication of 
apoptosis to corroborate the evidence of the rounding of cells experienced upon 
exposure to 1 mg/mL GTE. This can also be corroborated with the use of 
apoptosis assay kits, such as the detection of loss of MMP experienced in the early 
stage of apoptosis as previously used in GTE hepatotoxicity studies.38 Additionally, 
the use of ATP or DNA assays may be more appropriate to avoid the interference 






Improving our understanding of GTE-related liver injury, which has been reported 
to be related to catechins, requires detailed biochemical investigation, which can 
be achieved using metabolomic analyses. This was applied in this project for the 
ability of metabolomics to characterise metabolites in a range of different GTE 
products and to determine their relative levels of different catechins in each 
product. Catechin levels varied widely among different GTE products, suggesting 
that changes in chemical composition of GTE products is associated with 
environmental conditions and manufacturing practices. Studies have suggested 
lethal doses of the catechins within in vivo models, and these variations may have 
implications in GTE hepatotoxicity. The other components of the GTE products 
were putatively identified and included fatty and amino acids. Many metabolites 
were identified to be chemicals used in the derivatisation process, and future 
studies may require utilisation of a greater number of mass spectral databases for 
correct identification.  
Metabolomic techniques were also applied to characterise the biochemical 
pathways of GTE-induced hepatotoxicity in liver cells. GTE-exposed HepG2 cells 
responded in a dose-dependent manner, with decreasing structural integrity and 
cell viability. An MTT assay was used to confirm decreases in cell viability, but 
conflicted with Trypan blue results due to evidence of formazan production from 
flavonoids. Exposure to 1 mg/mL GTE induced more significant fold decreases 
in metabolites of HepG2 cells, including amino acids and oxoacids, compared to 




hepatoxicity is a dose-dependent process that may induce ROS production, ATP 
depletion and apoptosis, as corroborated by other studies.  
Metabolomics is an emerging field that allows us to study the final downstream 
phenotype of an organism, identifying cellular pathways pertaining to abnormal 
changes in biochemistry. Although subsequent studies will require in vivo 
techniques and improvement in metabolite identification, this preliminary study 
further elucidated the biochemical pathways involved in GTE hepatotoxicity 
through novel metabolomic studies not yet employed in this research field. 
Additionally, this study contributed to determination of the chemical composition 
of different GTE products and characterisation of their changes in tea catechins 
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